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Summary 
Erythropoietin (Epo) acts as the key regulator of red blood cell development in mammals. 
During erythropoiesis, Epo initiates the JAK2/STAT5 signal transduction pathway that elicits 
pro-survival signals in erythroid progenitor cells. Therefore, the tight regulation of 
JAK2/STAT5 signaling is crucial for the fine-tuned balance of erythrocyte production. 
Recently, several factors regulating Epo-induced JAK2/STAT5 signaling have been 
identified. However, their relative contribution in controlling the dynamic behavior of 
JAK2/STAT5 signaling is poorly understood. To elucidate the specific roles of these negative 
regulators in attenuating the pathway, data-based mathematical modeling was employed. 
In this study, standardized protocols were established facilitating the generation of 
quantitative time-resolved data of Epo-induced JAK2/STAT5 pathway activation in primary 
erythroid progenitor cells and the hematopoietic cell line BaF3-EpoR, which is a frequently 
used model system to study EpoR signaling. For the fine-tuned overexpression of negative 
regulators in hematopoietic cells, an inducible Tet-On retroviral vector system was 
developed. Systematic comparison of stoichiometries and activation dynamics of Epo-
induced JAK2/STAT5 signaling in CFU-E and BaF3-EpoR cells revealed fundamental 
differences between both cell types, emphasizing the importance of the use of primary cells 
in the investigation of EpoR signaling. Genome-wide expression profiling identified potential 
feedback regulators of Epo-induced JAK2/STAT5 signaling in CFU-E cells. To dissect the 
complex roles of negative regulators that employ different mechanisms to attenuate 
JAK2/STAT5 signaling, a data-based dynamic pathway model was established. Calibration 
of the mathematical model was performed using multiple experimental data sets of Epo-
induced JAK2/STAT5 signaling monitored under different conditions. The estimated 
parameters were fully identifiable and displayed small confidence intervals, which are 
required for accurate simulations. Comprehensive model analysis identified the rapid 
recruitment of the phosphatase SHP-1 as major mechanism controlling the early-phase 
kinetics of pathway activation, while the two transcriptionally induced regulators SOCS3 and 
CIS were elucidated as modulators of the STAT5 steady-state phosphorylation level. 
Furthermore, global sensitivity analysis uncovered the concentrations of SHP-1 and JAK2 as 
well as the parameter SOCS3 expression as critical to control the integral signal strength of 
nuclear phosphorylated STAT5, which is proportionally linked to the survival of erythroid 
progenitor cells. 
In conclusion, by combining mathematical modeling with experimental data, the crucial 
regulators enabling the tight control of Epo-induced JAK2/STAT5 signaling were elucidated. 
The detailed understanding of the molecular processes and regulatory mechanisms of Epo-
induced signaling during normal erythropoiesis can be further exploited to gain insights into 
alterations promoting erythroleukemia and related malignant hematopoietic diseases. 
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Zusammenfassung 
Erythropoetin (Epo) ist der zentrale Regulator der Bildung roter Blutzellen in Säugetieren. 
Während der Erythropoese aktiviert Epo den JAK2/STAT5 Signalweg, der 
Überlebenssignale in erythropoetischen Vorläuferzellen auslöst. Daher ist die präzise 
Regulation des JAK2/STAT5 Signalweges wichtig für das feinabgestimmte Gleichgewicht der 
Produktion von Erythrozyten. Kürzlich wurden mehrere Faktoren identifiziert, die den Epo-
induzierten JAK2/STAT5 Signalweg regulieren. Eine wesentliche Frage ist, zu welchem 
Anteil diese Modulatoren das dynamische Verhalten des JAK2/STAT5 Signalweges steuern. 
Um die spezifische Rolle der negativen Regulatoren bei der Abschaltung des Signalweges 
zu identifizieren, wurde ein datenbasierter mathematischer Modellierungsansatz gewählt. 
Zur Erzeugung quantitativer und zeitaufgelöster Daten der Aktivierung des Epo-induzierten 
JAK2/STAT5 Signalweges in primären erythroiden Vorläuferzellen und der 
hematopoetischen Zellinie BaF3-EpoR, die ein häufig genutztes Modellsystem für die 
Untersuchung von EpoR-Signalwegen ist, wurden standardisierte Protokolle etabliert. 
Desweiteren wurde ein induzierbares retrovirales Tet-On Vektorsystem entwickelt, um eine 
feinregulierte Überexpression von negativen Regulatoren in hematopoetischen Zellen zu 
ermöglichen. Der systematische Vergleich von Stöchiometrien und der Aktivierungsdynamik 
des Epo-induzierten JAK2/STAT5 Signalweges in CFU-E und BaF3-EpoR Zellen zeigte 
grundlegende Unterschiede zwischen beiden Zelltypen auf und verdeutlichte die Bedeutung 
von Primärzellen in der Untersuchung von EpoR-abhängigen Signalwegen. Durch eine 
genomweite Expressionsanalyse konnten potentielle negative Regulatoren des Epo-
induzierten JAK2/STAT5 Signalweges in CFU-E Zellen identifiziert werden. Zur 
Untersuchung der komplexen Rolle von negativen Rückkopplungs-(feedback) Regulatoren, 
die den JAK2/STAT5 Signalweg durch unterschiedliche Mechanismen abschalten, wurde ein 
datenbasiertes Modell des JAK2/STAT5 Signalweges erstellt. Die Kalibrierung des Modells 
erfolgte mittels umfangreicher quantitativer Daten, die unter unterschiedlichen Bedingungen 
generiert wurden. Die bestimmten Parameter waren vollständig identifizierbar und wiesen 
kleine Konfidenzintervalle auf, die wichtig für akkurate Simulationen sind. Eine umfassende 
Modellanalyse identifizierte die schnelle Rekrutierung der Phosphatase SHP-1 als einen 
zentralen Mechanismus zur Regulierung der frühen Aktivierungsphase, während die zwei 
transkriptionell induzierten Regulatoren CIS und SOCS3 als Modulatoren der 
Phosphorylierung von STAT5 in der steady state-Phase nachgewiesen wurden. Darüber 
hinaus konnten durch eine globale Sensitivitätsanalyse die Konzentration von SHP-1 und 
JAK2 sowie der Parameter SOCS3 Expression als kritische Faktoren bei der Kontrolle der 
integralen Signalstärke des nukleären phosphorylierten STAT5 identifiziert werden, die 
proportional mit der Überlebensrate von erythropoetische Vorläuferzellen verknüpft ist. 
Zusammenfassend konnte durch die Kombination von mathematischer Modellierung und 
quantitativen experimentellen Daten die zentralen Regulatoren identifiziert werden, die eine 
präzise Kontrolle des Epo-induzierten JAK2/STAT5 Signalweges ermöglichen. Die 
detaillierten Erkenntnisse der regulatorischen Mechanismen von Epo-induzierten 
Signalwegen während der Erythropoese können weiterhin genutzt werden, um Einblicke in 
molekulare Prozesse zu gewinnen, die Erythroleukämien und verwandte hematopoetische 
Krankheiten induzieren. 
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1 Introduction 
Eukaryotic cells communicate via extracellular signaling molecules to control multiple cellular 
processes within an organism. By interacting with specific cell surface receptors on target 
cells these messengers trigger cytoplasmic signal transduction pathways, which lead to the 
modification of gene expression and thus regulate cellular decisions. Depending on the 
specific cell context and stimulus the response involves proliferation, differentiation, migration 
or survival.  
1.1 Signaling through cytokine receptors 
An important group of extracellular signaling molecules are small secreted glycoproteins, 
called cytokines, that operate at very low concentrations. Cytokines include interferons 
(IFNs), interleukines (ILs), chemokines, and factors that induce the formation of blood cells. 
They are primarily involved in the development and regulation of the immune system, 
hematopoiesis and developmental processes during embryogenesis. Secreted by a wide 
variety of cells, their mode of action may be endocrine, paracrine or autocrine. To initiate 
their specific functions, they interact with cell surface receptors of the cytokine receptor 
superfamily, which are classified in type I, e.g. IL2-6, erythropoietin (Epo), prolactin (PR), 
growth hormone (GH), and type II, e.g. IFN-α, -β, -γ receptors. Functional receptors consist of 
a signal-receiving extracellular domain, a single transmembrane domain, and a signal-
transducing cytoplasmic domain that lacks intrinsic enzymatic activity and therefore 
associates with members of the Janus kinase (JAK) family to initiate intracellular signal 
transduction pathways (Aaronson and Horvath, 2002). Although many different signaling 
cascades are activated by cytokine receptors, the JAK/ signal transducer and activator of 
transcription (STAT) pathway plays a central role in transmitting and processing the 
information received from cytokines within eukaryotic cells. 
1.1.1 The JAK/STAT signaling pathway 
JAKs have first been described by studies of transcriptional activation in response to 
interferon α (IFNα) and interferon γ (IFNγ) (Schindler et al., 1992). They represent a family of 
four non-receptor tyrosine kinases, JAK1, JAK2, JAK3 and Tyk2. Being pre-associated with 
the cytoplasmic domain of cytokine receptors, these kinases are activated by trans-
phosphorylation upon cytokine-induced receptor dimerization or re-organization. Activated 
JAKs subsequently phosphorylate tyrosine residues within the cytoplasmic tail of the 
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receptor, providing docking sites for SH2 domain containing STATs (Aaronson et al., 2002). 
STATs comprise a family of seven structurally and functionally related proteins: STAT1, 
STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. As latent transcription factors, 
STATs reside in the cytoplasm until they become activated by tyrosine phosphorylation (Fig. 
1). Phosphorylated STATs rapidly dimerize and translocate into the nucleus to activate gene 
transcription (Levy and Darnell, 2002). For this purpose, they bind to gamma-activated 
sequence (GAS) elements in the promoter regions of their target genes that are 
characterized by the consensus sequence TTNCNNNAA (Horvath, 2000; Xu et al., 1996). 
The precise mechanism of STAT entry into the nucleus still remains unknown. The large size 
of these protein complexes (~180 kD for the STAT dimer) implies that they require facilitated 
transport in the nucleus (Mattaj and Englmeier, 1998). Binding of STAT to importin, one of 
the subunits of the nucleocytoplasmic transport machinery, has been described and, in at 
least some cells, also unphosphorylated STATs can enter the nucleus (Reich and Liu, 2006). 
Dephosphorylation of STAT occurs in the nucleus and is an important signal for the export 
into the cytoplasm, which may be mediated by Crm1, a nuclear export protein (Marg et al., 
2004).  
 
 
Fig. 1. The JAK/STAT signal transduction pathway. 
Cytokine-induced receptor oligomerization or 
reorganization activates pre-associated JAKs by 
tyrosine trans-phosphorylation. Activated JAKs 
phosphorylate tyrosine residues of the cytoplasmic 
domain of cytokine receptors, thereby providing binding 
sites for SH2-domain containing STATs. STAT 
molecules become tyrosine-phosphorylated by JAKs, 
dissociate from the receptor and dimerize. STAT dimers 
translocate to the nucleus and induce target gene 
expression. After dephosphorylation in the nucleus, the 
dimers dissociate and monomeric STATs re-enter the 
cytoplasm. 
 
1.1.2 Structure and function of JAKs and STATs 
The unique structure of JAKs clearly distinguishes them from other members of protein 
tyrosine kinase families. The most intriguing feature of these proteins are two adjacent 
domains: a C-terminal kinase domain (JAK homology 1, JH1) and a catalytically inactive 
pseudokinase domain (JH2), which has a kinase domain fold but lacks crucial residues for 
catalytic activity and for nucleotide binding (Baker et al., 2007) (Fig. 2). This characteristic 
structure gives the family their name after Janus, the Roman God of gates and doors who is 
represented by a double-faced head looking in opposite directions. Growing evidence 
indicates that the JH2 domain is required for inhibiting the basal activity of the kinase domain 
(Saharinen and Silvennoinen, 2002; Saharinen et al., 2003). The N-terminal half of JAKs 
Introduction  11 
contains two motifs, a region (JH3-4) resembling a src-homology (SH2) domain and a four-
point-one, Ezrin, Radixin, Moesin (FERM) domain. Despite of the homology to SH2 
sequences, the SH2-like domain does not appear to bind phosphotyrosine residues and its 
function still remains to be defined (Higgins et al., 1996; Radtke et al., 2005). The FERM 
domain (JH6-7) has been shown to mediate association with receptors by binding to the 
box1/proline-rich membrane proximal region of cytokine receptors (Pellegrini and Dusanter-
Fourt, 1997). Moreover, recent studies suggested that residues within the FERM domain are 
important for hydrophobic core stabilization and also catalytic function (Haan et al., 2008). 
 
 
 
Fig. 2. Domain structure of Janus kinases (JAKs) and signal transducers and activators of 
transcription (STATs). Sequence analysis indicated conserved domains for JAKs and STATs. JAKs 
contain seven JAK homology domains (JH1-7). The catalytic activity of the kinase domain JH1 is 
regulated by interaction with the pseudo-kinase domain JH2. JH3-JH7 mediate protein-protein 
interactions, e.g. receptor association. STATs contain six defined domains. The N-terminal region is 
critical for STAT function, i.e. nuclear import and export. The coiled domain is involved in receptor 
binding and association with regulatory proteins. The SH2 domain binds to specific phospho-tyrosine 
residues of other STATs or of receptors. The C-terminal transactivation domain (TAD) varies among 
family members and its detailed function is not fully understood. Abbreviations see text. 
 
Similar to most transcription factors, STATs exhibit a modular structure with six well-defined 
domains, including an N-terminal conserved domain, a coiled-coil domain, a DNA binding 
domain, a linker region, a SH2 domain and a C-terminal transactivation domain (TAD). This 
structure was defined by homology studies and crystallographic analysis of the core amino 
acids (130-710) of either dimeric STAT1 or dimeric STAT3 bound to DNA (Chen et al., 1998). 
The N-terminal region of STATs is well conserved among all family members and appears to 
be critical for STAT function, i.e. nuclear import, export or receptor binding. The coiled-coil 
domain adopts an alpha-helical conformation, functions in receptor binding and associates 
with regulatory proteins (Kisseleva et al., 2002). The DNA-binding domain is highly 
conserved among STATs. The linker domain functions as a spacer to maintain proper 
conformation between the dimerization and the DNA-binding domains. The SH2 domain is 
critical for the recruitment of STATs to activated receptor complexes and for STAT 
dimerization. Directly downstream of the SH2 domain around position 700, all STATs contain 
a tyrosine residue that has been found to be essential for the activation and dimerization of 
STATs (Darnell, 1997; Schindler and Darnell, 1995). In addition to tyrosine phosphorylation, 
several STATs are regulated by serine phosphorylation that is mediated by serine/threonine 
kinases including p38 or JNK (Khwaja, 2006). The transactivation domain varies among 
family members and its detailed function and specificity in transcriptional regulation of 
different STAT isoforms remains to be determined.  
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1.2 Negative regulation of cytokine signaling 
Regulation of the initiation, strength and duration of JAK/STAT signaling is crucial for the 
control and fine-tuning of cytokine responses. Recently, several mechanisms of negative 
feedback inhibition have been suggested to be involved in the attenuation of cytokine 
responses at multiple levels (Fig. 3). These include protein tyrosine phosphatases (PTPs), 
suppressors of cytokine signaling (SOCS), protein inhibitors of activated STATs (PIAS), and 
degradation of JAK/receptor complexes through receptor-mediated endocytosis (O'Sullivan 
et al., 2007). Although a large number of negative regulators have been identified, the 
specificity and timing of these negative regulators in downregulation of distinct cytokine-
induced responses are still elusive. For instance, SOCS proteins are induced in response to 
cytokines whereas phosphatases are constitutively expressed and may act as very early 
response regulators. 
 
 
Fig. 3. Negative regulation of the JAK/STAT pathway. JAK/STAT signaling is regulated at various 
levels. Receptor internalization and degradation control the numbers of receptors at the cell surface. 
Phosphotyrosine phosphatases (PTPs) deactivate JAKs and receptors. Suppressors of cytokine 
signaling (SOCS) are induced upon cytokine stimulation and negatively regulate signaling by 
inhibition of kinase activity, by competing with STATs for phosphotyrosine binding sites on receptors 
and by promoting ubiquitination, and subsequent proteasome-mediated degradation of JAKs. Protein 
inhibitors of activated STATs (PIAS) bind to activated STAT dimers and inhibit transcription. Adapted 
from O’Sullivan et al., 2007. 
 
1.2.1 Protein tyrosine phosphatases (PTPs) 
Tyrosine phosphorylation levels are determined by the antagonistic actions of protein 
tyrosine kinases and protein tyrosine phosphatases (PTPs) (Pallen et al., 1992). In the 
JAK/STAT pathway three groups of PTPs have been proposed to regulate signaling. These 
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include (i) the SH2-containing phosphatases (SHPs) SHP-1 and SHP-2, (ii) the 
transmembrane tyrosine phosphatase CD45 as well as the (iii) phosphotyrosine phosphatase 
1B (PTP1B) and the T-cell protein tyrosine phosphatase (TC-PTP). 
SHPs SHP-1 and SHP-2 belong to a subfamily of non-transmembrane PTPs and are 
characterized by two N-terminal SH2 domains, a classic phosphatase domain and a C-
terminal tail (Fig. 4). SHP-1 is predominantly expressed in hematopoietic cells, while 
expression of SHP2 is more ubiquitous (Banville et al., 1995). Recruitment of SHP-1 to 
activated receptors and JAKs via its SH2 domains causes dephosphorylation and 
inactivation of JAKs (Jiao et al., 1996; Ward et al., 2000). Importantly, mutation of the 
phosphotyrosine residues to which SHP-1 binds on the receptors for Epo, IL-3,-5 and GM-
CSF results in sustained JAK activation (Klingmüller et al., 1995; Yi et al., 1993). In contrast, 
SHP-2 has been reported to function as both a positive and negative regulator of cytokine 
receptor signaling (Neel et al., 2003). Biochemical studies and the crystal structure of C-
terminally truncated forms of SHP-1 and SHP-2 revealed an intramolecular regulatory 
mechanism that effectively links subcellular localization of SHPs with the phosphatase 
activity (Pao et al., 2007a). In the inactive state, the N-terminal SH2-domain blocks access of 
substrates to the active site and thereby inhibits the phosphatase domain. Binding of the N-
terminal SH2-domain to a phosphotyrosine residue causes the release from the active site, 
leading to enzyme activation (Poole and Jones, 2005). Mice deficient for SHP-1 activity 
(motheaten, me/me) display severe immunological and hematopoietic dysfunctions (Shultz et 
al., 1993) and hyperphosphorylation of JAK1 and JAK2 following IFNα, GH or EPO treatment 
was observed (Jiao et al., 1996). 
CD45 The second type of tyrosine phosphatase that was proposed to negatively regulate 
JAK/STAT signaling is the transmembrane tyrosine phosphatase CD45, which is expressed 
in hematopoietic cells and is a key regulator of T-cell and B-cell antigen receptor signaling in 
T- and B-lymphocytes. In vitro, CD45 directly binds to and dephosphorylates JAKs and 
negatively regulates IL-3 mediated cellular proliferation (Irie-Sasaki et al., 2001). 
PTP1B and TC-PTP Phosphotyrosine phosphatase 1B (PTP1B) and T-cell protein tyrosine 
phosphatase (TC-PTP) share sequence similarities in their catalytic domains and comprise 
the third group of phosphatases that regulate JAK/STAT signaling. PTP1B is localized to the 
endoplasmic reticulum and is expressed in several tissues. TC-PTP, on the other hand, is 
primarily expressed in hematopoietic cell types and exists in two forms due to alternative 
splicing. The longer isoform (TC48) resides in the cytoplasm, whereas p45 (TC45) is 
localized to the nucleus. JAK2 and TYK2 are physiological substrates of PTP1B (Myers et 
al., 2001) whereas JAK1 and JAK3 are substrates of TC-PTP (Simoncic et al., 2002). TC45 
also has been shown to inactivate STAT1 and STAT3 (ten Hoeve et al., 2002). 
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Fig. 4. Domain structure of exemplary negative regulators of JAK/STAT signaling. Sequence 
analysis indicated conserved domains for the tyrosine phosphatases SHP-1 and SHP-2 as well as for 
CIS and SOCS1/3. SHPs contain two C-terminal SH2 domains mediating protein-protein interactions. 
CIS/SOCS contain one SH2 domain and a SOCS box that associates with E3-ligase complexes, 
mediating proteasomal degradation. Additionally, SOCS1/3 contain a kinase inhibitory region (KIR) to 
bind to JAKs and block catalytic activity by acting as a pseudo-substrate. 
 
1.2.2 Suppressors of cytokine signaling (SOCS) 
In contrast to the constitutively expressed phosphatases, suppressors of cytokine signaling 
(SOCS) proteins are transcriptionally induced negative regulators. They comprise a family of 
at least eight members: the cytokine-inducible SH2 domain containing protein (CIS) and 
SOCS1-7 (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997). They all contain a variable 
N-terminal region, a central SH2 domain and a C-terminal SOCS box that has been 
implicated in proteasomal degradation (Fig. 4). Following cytokine stimulation SOCS proteins 
are rapidly upregulated and the presence of STAT consensus sequences in their promoters 
suggests that their expression is regulated as part of a negative feedback loop (Matsumoto 
et al., 1997; Valentino and Pierre, 2006; Verdier et al., 1998b; Yoshimura et al., 1995). There 
are three general mechanisms by which SOCS proteins can regulate JAK/STAT activity. 
First, CIS and SOCS3 have been shown to compete with STATs for binding sites on 
receptors. Second, for SOCS1 and SOCS3 was reported that they can bind to JAKs directly 
via their kinase inhibitory region (KIR) that acts as a pseudosubstrate and thus prevent 
access of genuine substrates to the catalytic pocket (Elliott and Johnston, 2004). Third, 
SOCS proteins can downregulate JAK/STAT signaling by promoting ubiquitination and 
subsequent proteasome-mediated degradation of JAKs. Thereby, binding of elongin C to the 
SOCS box recruits an E3 ubiquitin ligase complex that targets bound proteins to proteolytic 
degradation (Ilangumaran et al., 2004). However, the physiological roles of specific SOCS 
proteins in controlling the different cytokine-induced signaling pathways as well as the timing 
and specificity of each of these mechanisms remain to be determined. 
1.2.3 Protein inhibitors of activated STATs (PIAS) 
Protein inhibitors of activated STATs (PIAS) family proteins were originally described as 
negative regulators of STATs, although they exhibit activity towards a variety of transcription 
factors. Five PIAS proteins including PIAS1, PIASx, PIASy, PIAS3α and PIASβ with various 
splicing isoforms have been described. They negatively regulate signaling by binding to 
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activated STAT dimers and inhibit transcription by distinct mechanisms. PIAS1 and PIAS3 
associate with STAT1 and STAT3, respectively, and directly inhibit DNA binding. PIASx has 
been shown to regulate the recruitment of transcriptional repressors such as histone 
deacetylaes (HDACs) (Rakesh and Agrawal, 2005). Furthermore, recent studies have 
demonstrated that some PIAS family members possess small ubiquitin-like modifier (SUMO) 
E3-ligase activity and mediate the SUMOylation of STATs, which can modify the 
transcriptional activity (Ungureanu et al., 2005). 
1.2.4 Dysregulated JAK/STAT signaling in hematopoietic diseases 
Dysregulated JAK/STAT signaling has been associated with a number of hematological 
malignancies including chronic and acute leukemias as well as myeloproliferative diseases, 
i.e. polycytemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis 
(IMF). Constitutive activation of STATs is a common characteristic that is caused by several 
mechanisms including downregulation of negative regulators, amplification of the JAK locus, 
JAK fusion proteins and activating point mutations in JAK2 (Khwaja, 2006).  
The first direct evidence implicating dysregulation of the JAK/STAT pathway in hematopoietic 
malignancies was the identification of TEL-JAK2 fusions in lymphoid and myeloid leukemias 
(Lacronique et al., 1997). In this fusion protein the helix-loop-helix oligomerization domain of 
the transcription factor TEL is fused to the catalytic JH1 domain of JAK2, leading to 
constitutive association and activation of STAT proteins (Ho et al., 1999; Schwaller et al., 
1998). Recently, several new JAK mutations have been identified that encode constitutively 
active or hyperactive JAK proteins. In particular, the constitutive active JAK2-V617F mutant 
has been identified in the majority of PV patients and in approximately 50 % of ET and IMF 
patients (Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 2005). 
This mutation is believed to disrupt the inhibitory role of the JH2 pseudokinase domain. In 
addition, JAKs and STATs are also known to be constitutively activated in hematopoietic 
cells transformed by oncogenic tyrosine kinases such as Bcr-Abl (Chai et al., 1997). 
Although STAT mutations have not been found in cancer so far, certain STATs have 
oncogenic potential and therefore may play an important role in human tumors. In particular, 
a STAT3 mutant, denoted STAT3-C, in which two residues within the C-terminal loop of the 
SH2 domain are substituted by cysteines, is constitutive active and has oncogenic potential 
(Bromberg et al., 1999). Furthermore, using PCR driven mutagenesis, a constitutive active 
STAT5 mutant, termed STAT5 1*6, was isolated, that was found to render BaF3 cells 
cytokine-independent (Nosaka et al., 1999). 
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1.3 Erythropoietin receptor controlling erythropoiesis 
1.3.1 Erythropoiesis 
Hematopoietic cytokines tightly control the development of blood cells. Because most mature 
blood cells are short-lived, the different cell lineages are continuously renewed during 
embryogenesis and throughout lifetime by hematopoietic stem cells (HSCs) (Weissman, 
2000). During hematopoiesis, the HSCs develop into progenitors that become progressively 
restricted to lineage precursors that further proliferate and differentiate into mature blood 
cells including erythrocytes, megacaryocytes, myeloid cells (monocytes/macrophage and 
neutrophils), and lymphocytes (Orkin and Zon, 2008). The process of differentation into 
hematopoietic lineages is regulated by pleiotropic cytokines or by a lineage specific 
cytokines. 
In erythropoiesis, the development of red blood cells, erythropoietin (Epo) is the primary 
regulator. Erythrocytes are the most common type of blood cells and function as transporters 
of oxygen between lungs and tissue in the vertebrate body. Because they possess a short 
lifespan of approximately 120 days in human and 40 days in mice they undergo continuous 
renewal. In murine development, erythrocytes are being produced in stage-dependent 
distinct locations (Fig. 5).  
 
 
 
Fig. 5. Developmental regulation of erythropoiesis in the mouse. (a) Developmental time 
windows for distinct stages of erythropoiesis within the murine embryo. (b) Erythropoiesis first occurs 
in the yolk sac blood islands (primitive erythropoiesis) and later in the fetal liver (definitive 
erythropoiesis) before production shifts to the bone marrow. Yolk sac and fetal liver are visualized by 
LacZ staining. Adapted from Orkin et al., 2008 
 
In the fetus, the first sites of erythrocyte production are the blood islands in the yolk sac. At 
this stage of primitive erythropoiesis, large nucleated erythrocytes are synthesized that 
express embryonic hemoglobin and are not dependent on Epo (Wu et al., 1995). Around day 
12 of gestation (E12), the production of red blood cells shifts to the fetal liver, generating 
Introduction  17 
non-nucleated definitive erythrocytes that express both embryonic and adult hemoglobins. 
Shortly before birth, definitive erythropoiesis relocates to the bone marrow and the spleen, 
which become the dominant sites of erythrocyte production throughout life (Hoffman, 1995). 
During erythropoiesis in the fetal liver or the bone marrow (Fig. 6), the earliest committed 
progenitors identified ex vivo are the burst-forming units-erythroid (BFU-Es). In the presence 
of stem cell factor (SCF), interleukin-3 (IL-3), and erythropoietin (Epo), BFU-Es further 
progress into the colony-forming units-erythroid (CFU-E). The two types of progenitors are 
identified in vitro by the colonies they produce in colony-formation assays. Murine BFU-E 
colonies require 7-10 days to form in culture whereas CFU-E colonies require 2 days of 
cultivation in semi-solid medium (Gregory and Eaves, 1977).  
 
 
Fig. 6. Schematic overview depicting the formation of erythrocytes from the HSC during murine 
definitive erythropoiesis. The HSC gives rise to the colony forming unit-granulocyte-erythroid-
makrophage-megakaryocyte (CFU-GEMM), which develops to the BFU-E after commitment to the 
erythroid lineage. Under the influence of SCF, IL-3, and Epo, the cells progress from the BFU-E stage 
to the CFU-E stage which is strictly Epo-dependent. The CFU-E further develop into erythroblasts 
under tight control of Epo signaling. After ejection of the nucleus, the reticulocytes enter the blood 
stream and mature to erythrocytes. Adapted from U. Klingmüller, 1997. Abbreviations see text. 
 
In the presence of Epo, CFU-Es mature progressively through four different stages: pro-
erythroblasts, basophilic, polychromatophilic and orthochromatophilic erythroblasts. When 
differentiation proceeds, erythroblasts display a gradual decrease in cell size, increase in 
chromatin condensation and increase in hemoglobin content. Finally, the nucleus is extruded 
and reticulocytes are formed that detach from their environment to enter the blood stream. 
By further expelling all organelles they mature to oxygen-carrying erythrocytes (Hoffman, 
1995). The Epo receptor (EpoR) is first expressed at the BFU-E stage and most strongly in 
cells of the CFU-E stage. Beyond the late erythroblast stages, the expression of the receptor 
decreases and these cells are no longer dependent on Epo. 
1.3.2 Erythropoietin and erythropoietin receptor 
The physiological role of Epo and EpoR in erythropoiesis has been primarily determined 
using mice harboring null mutations in genes encoding either Epo or the EpoR. These 
knockout mice die during embryogenesis at day E12.5-E13.5, which is the stage of massive 
erythroid expansion. Fetal livers of these mice contain normal numbers of committed CFU-E, 
indicating that Epo signaling is dispensable at earlier stages of hematopoiesis (Richmond et 
al., 2005). During embryogenesis, Epo is produced in the fetal liver whereas in the adult, Epo 
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is primarily expressed in the tubular, juxtatubular endothelial, and interstitial cells of the 
kidney as well as extrarenally in hepatocytes and Kupffer cells (Krantz, 1991). Low oxygen 
tension in the tissue due to blood loss or high altitude strongly induces expression of the Epo 
gene by means of the hypoxia-inducible transcription factors HIF-1 and HIF-2 (Ebert and 
Bunn, 1999). As typical cytokine, Epo consists of four α-helices that are folded into a 
compact globular structure. The carbohydrate chains of the glycoprotein are required for full 
biological activity in vivo. 
The murine EpoR belongs to the family of type I cytokine receptors that is composed of an 
extracellular N-terminal ligand-binding domain, one single transmembrane domain and a 
cytosolic domain that lacks enzymatic activity (D'Andrea et al., 1989). The extracellular 
domain contains two fibronectin type II domains, D1 and D2. Each subdomain contains two 
conserved cysteine residues that form disulfid bonds. The amino acid motif WSXWS that is 
conserved among the hematopoietic cytokine receptor superfamily, is located in proximity to 
the transmembrane domain (Bazan, 1990; Cosman et al., 1990). The signal-transducing 
cytoplasmic domain contains two proline-rich motifs Box1 and Box 2 that are required for 
JAK2 function (Huang et al., 2001). Mutations of the EpoR that cause expression of 
truncated EpoR variants have been implicated in primary familial polycythemias (de la 
Chapelle et al., 1993; Kralovics et al., 1997). This benign erythrocytosis is characterized by 
elevated red blood cell mass and low serum Epo level. Cultured erythroid progenitors from 
these patients show increased Epo-sensitivity compared to cells expressing the wild-type 
EpoR. 
1.3.3 Signaling through the erythropoietin receptor 
Signaling through the EpoR promotes cell survival, enhances proliferation and supports 
differentiation in erythropoiesis at the BFU-E stage through the CFU-E stage to late 
erythroblasts. Over the past decade, the major signaling proteins activated by Epo have 
been identified. As a typical cytokine receptor, the EpoR lacks intrinsic kinase activity and 
associates with the tyrosine kinase JAK2 that is involved in the activation of downstream 
pathways. The absolute requirement for JAK2 to transduce EpoR signals was substantiated 
by analyses of JAK2 knockout mice that die between E13 and E15 from severe anemia, 
demonstrating an essential role of JAK2 in definitive erythropoiesis (Neubauer et al., 1998). 
Upon binding of Epo and structural rearrangements of the EpoR cytoplasmic domain, JAK2 
is rapidly activated by transphosphorylation on tyrosine 1007 in its activation loop (Feng et 
al., 1997). In turn, JAK2 phosphorylates several tyrosine residues within the EpoR 
cytoplasmic domain which serve as docking sites for SH2 domain-containing effectors. The 
signaling molecules und pathways activated upon recruitment to the phosphorylated EpoR 
include STAT5, phosphatidylinositol 3-kinase (PI3-K), mitogen-activated protein kinase 
(MAPK) and protein kinase C (PKC).  
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Fig. 7. Signaling pathways activated by the EpoR. Upon Epo binding to the preformed receptor 
dimer, JAK2 gets activated by transphosphorylation and in turn phosphorylates the EpoR on several 
cytoplasmic tyrosine residues. Several signaling pathways emanate from the EpoR, including the 
RAF/Mek/ERK and the Akt/PKB cascade. The most direct way of signal transduction through the 
EpoR is the activation of the transcription factor STAT5. Induction of CIS represents a negative 
feedback loop for STAT5 activity. In addition to SOCS proteins, downregulation of EpoR signaling is 
mediated by recruitment of protein tyrosine phosphatases including SHP-1. Abbreviations see text. 
 
STAT5 signaling  
The most direct way to transmit receptor stimulation to the nucleus is the activation of 
STAT5. The latent transcription factor associates with phosphorylated residues Y343 and 
Y401 on the activated EpoR which is sufficient for maximal STAT5 phosphorylation. The 
binding to phosphotyrosines 429 and 431 only results in partial STAT5 activation (Klingmüller 
et al., 1996). Upon phosphorylation, STAT5 dissociates from the receptor, dimerizes, 
translocates to the nucleus and binds to cognate elements in various promoters to activate 
transcription of target genes. These include the negative regulators CIS (Matsumoto et al., 
1997) and SOCS-3 as well as targets such as Pim-1, c-myc, OncostatinM, Bcl-xL or D-type 
cyclins that are required for functional erythropoiesis (Menon et al., 2006; Silva et al., 1999; 
Socolovsky et al., 1999). 
The physiological role of STAT5 in erythropoiesis has been extensively studied in the last 
years. Although discussed controversially, increasing evidence suggests that STAT5 
promotes survival in erythroid progenitor cells by directly inducing the expression of the anti-
apoptotic protein Bcl-xL (Garcon et al., 2006; Socolovsky et al., 1999). STAT5ab-/- mice 
display fetal anemia and elevated rates of apoptosis of erythroid progenitor cells as a result 
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of a failure in Bcl-xL up-regulation (Socolovsky et al., 2001). Recently, a second study 
generated knockout mice of STAT5ab-/- and these mice are perinatally lethal and highly 
anemic in utero (Cui et al., 2004) which further supports the essential function of STAT5 
during erythropoiesis. 
 
MAP kinase and PI3 kinase signaling 
Besides phosphorylation of STAT5, Epo induces the activation of several mitogen-activated 
protein kinases (MAPK), including the extracellular-regulated kinase 1/2 (Erk1/2). For 
initiation of the MAPK cascade Grb2-Sos is recruited to the EpoR by several different routes. 
Grb2 can bind either directly to Y464 of the EpoR or indirectly by interacting with SHP-2 or 
SHIP-1 (Mason et al., 2000; Tauchi et al., 1996). Alternatively, SHC can bind to JAK2 and 
serve as adapter protein for Grb2 (He et al., 1995). Subsequently, Sos-catalyzed exchange 
of GDP for GTP on Ras results in activation of Ras which leads to the initiation of the MAPK 
cascade. An alternative route for MAPK has been proposed through activation of the protein 
kinase C (PKC) via the phosphatidylinositol 3 kinase (PI3-K) pathway (Karnitz and Abraham, 
1995). 
PI3-K is activated upon Epo stimulation via two possible mechanisms. In the direct way, the 
p85 regulatory domain of PI3-K is directly recruited to Y479 of the activated EpoR (Damen et 
al., 1995; Klingmüller, 1997). Additionally, PI3-K can be activated indirectly by recruitment of 
the Grb2-associated binder (Gab) (Bouscary et al., 2003; Ravichandran et al., 1995). 
Downstream of PI3-K, the protein kinase B (PKB/Akt) is activated. One of the PKB/Akt 
substrates includes the forkhead box O3A (Foxo3a) transcription factor that has been shown 
to play an important role in erythroid differentiation (Kashii et al., 2000). 
 
Termination of EpoR signaling 
Although the downstream signaling cascades induced by the activated EpoR are well 
studied, the mechanisms that terminate signaling are poorly understood. In the last decade 
several classic negative regulators of JAK/STAT signaling have been proposed to be 
involved in attenuation of EpoR signaling. In particular, recruitment of SHP-1 to 
phosphotyrosine Y429 and Y431 of the EpoR has been shown to dephosphorylate JAK2 
(Klingmüller et al., 1995) and potentially the EpoR. Moreover, four SOCS proteins have been 
associated with Epo-induced signaling: CIS, SOCS-1, SOCS2 and SOCS-3 (Pircher et al., 
2001; Starr et al., 1997; Yoshimura et al., 1995). CIS was identified to bind to the EpoR on 
phosphorylated Y401, thereby competing for receptor binding with STAT5 (Ketteler et al., 
2003). Other studies indicated that CIS is involved in proteasome-mediated inactivation of 
the EpoR (Verdier et al., 1998a). SOCS-3 was proposed to bind to activated EpoR and JAK2 
(Hortner et al., 2002; Sasaki et al., 2000) and both SOCS-1 and SOCS-3 have been 
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suggested to inhibit JAK2 activity by directly binding to the kinase activation loop (Sasaki et 
al., 1999; Ungureanu et al., 2002). However, most of these studies were performed in 
transformed cell lines, and the specific roles of these proteins in controlling EpoR signaling in 
erythropoiesis are still unclear. 
1.3.4 In vitro cell models to study erythropoiesis 
In the past years, the majorities of studies that investigated signaling pathways in 
erythropoiesis used transformed growth factor independent (erythro-) leukemia cell lines 
(Drexler et al., 2004). Moreover, partially transformed factor-dependent cell lines are a 
frequently used model system to study erythropoiesis. In particular, the IL-3 dependent 
murine pro-B cell line BaF3 is well established to study Epo-dependent signaling pathways 
by exogenously expressing the EpoR (Warmuth et al., 2007). However, cell lines may be 
genetically instable and exhibit major alterations in signaling pathways due to aberrant 
stoichiometries of signaling molecules, contributing to transformed cell growth (Wickrema 
and Crispino, 2007). For studying signaling pathways in erythropoiesis closely resembling 
the in vivo situation, the use of primary cells is indispensable. Erythroid progenitors at the 
CFU-E stage isolated from mouse fetal livers can be cultured under standardized conditions 
to investigate the regulation of proliferation, survival and the differentiation into mature 
erythrocytes. Nevertheless, the limited availability of primary erythroid progenitor cells and 
the short time span before they undergo differentiation is a major challenge for the 
investigation of molecular processes that are involved in the regulation of erythropoiesis. 
1.4 Systems biology approach 
1.4.1 Systems biology in signal transduction 
An enormous amount of qualitative information about the components of signal transduction 
pathways and their interplay has accumulated in the past decades. However, in order to 
understand how signaling networks are regulated and which parameters determine their 
dynamics, a static representation of the pathway components is not sufficient (Heinrich et al., 
2002). Mathematical modeling has emerged as a powerful tool in the last decade to analyze 
key features of signal transduction pathways involved in the regulation of systems behavior 
(Kholodenko, 2006; Kolch et al., 2005; Stelling et al., 2004). Progress in this area requires 
optimized quantitative data generation as well as advanced computational methods to make 
testable predictions and suggest experiments most informative for hypothesis-driven 
research in biology (Fig. 8). 
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Fig. 8. Iterative cycle of systems biology. 
Biological issues are adressed by an iterative 
cycle of quantitative experimental data 
generation, mathematical modeling, in silico 
predictions, experimental validation and design of 
new experiments. Adapted from Kitano, 2002. 
The pathways most extensively studied by systems biology approaches are the EGFR 
signaling network (Kholodenko et al., 1999; Kholodenko, 2007), the MAPK cascade (Orton et 
al., 2005) and NFkB signaling (Cheong and Levchenko, 2008; Nelson et al., 2004).  
Recently, several kinetic models of JAK/STAT signaling pathways have been established. 
The majority of these studies rely on previously published data and simulations. They were 
focused on coordination principles and control mechanisms of the IFNγ activated 
JAK1/JAK2/STAT1 pathway (Soebiyanto et al., 2007; Yamada et al., 2003; Zi et al., 2005), 
robustness in the JAK/STAT1 pathway (Shudo et al., 2007) or IL-6 induced JAK/STAT 
signaling in hepatocytes (Singh et al., 2006). However, very few data-driven models exist 
that directly combine quantitative data with dynamic pathway modeling. One example is the 
data-based mathematical model of the JAK2/STAT5 pathway in BaF3-EpoR cells that 
identified nucleocytoplasmic shuttling of STAT5 as the most sensitive step in the core 
module of JAK/STAT signaling (Swameye et al., 2003). Nevertheless, to understand how 
signaling pathways and in particular the JAK/STAT pathway are controlled and which are the 
most important proteins that regulate the outcome of the pathway, mathematical models 
based on reliable time-resolved and quantitative data should be established. 
1.4.2 Mathematical models 
The form of a mathematical model depends on the properties of the studied system and the 
goal of the modeling effort (Aldridge et al., 2006). The most commonly used models to study 
signal transduction pathways are based on coupled ordinary differential equations (ODEs). 
An ODE network thereby represents the rate of production and consumption of individual 
protein species in terms of mass action kinetics. Thus, each reversible biochemical 
transformation is represented by an elementary reaction with forward and reverse rate 
constants. If changes of proteins or molecules have to be modelled explicitly with respect to 
spatial distributions, partial differential equations (PDEs) are employed. Both ODE and PDE 
models can be cast either in deterministic form or using stochastic equations that include 
effects arising from random fluctuation around the average behavior (Kholodenko, 2006). 
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A first challenge in constructing a mathematical model of signal transduction pathways is 
specifying the scope and level of abstraction. If the scope of a model is too small, the 
predictive power is lost, whereas for too complex models with numerous species the 
uncertainty of predictions increases. Thus, an optimal compromise between complexity and 
oversimplification has to be made. After establishing the structure of the model, the 
parameters can be estimated using quantitative experimental data. In this process of model 
calibration, the values of parameters are computed to give the best fit to a set of 
experimental data using global optimizations methods (Banga, 2008). To validate the model 
experimentally, predictions are performed that can be subjected to experimental tests. 
Moreover, to improve the identifiability of parameters and to constrict the parameter space, 
an experimental design approach can be applied to systematically select the most 
informative experimental conditions by computational analysis (Maiwald et al., 2007). 
When the topology and parameters of the mathematical models have been determined and 
the parameter values are identifiable, the model can be applied to perform simulations of the 
dynamic behavior to gain insight into control and regulatory mechanisms and to suggest new 
experiments. Furthermore, sensitivity analysis can be applied that is a powerful tool for 
systematically determining which concentrations and rate constants in a given model have 
the largest impact on the behavior of signaling species or the output of the system 
(Westerhoff, 2008). 
1.4.3 Experimental technique for targeted perturbation - the Tet-inducible system 
When studying biological processes, the dynamics can only be identified from experimental 
data through systematic perturbations and subsequent response analysis. The observation 
of a system under altered conditions may also help to improve and validate mathematical 
models. However, one major difficulty in biological experiments is the targeted perturbation of 
cellular systems. Generally, unspecific inhibitors such as the generic inhibitor of transcription, 
actinomycin D can be employed. Other frequently used methods to challenge the dynamic 
behavior are the increase of protein levels by overexpression or knockdown by RNA 
interference (siRNA). An advanced tool facilitating the dose- and time-dependent 
overexpression of signaling components is the Tetracycline-inducible (Tet-) system. 
Tet-systems have been widely applied to control gene expression in eukaryotes (Baron and 
Bujard, 2000). The principle of these regulatory systems is based on the E.coli tetracycline 
resistance operon (Tn10) consisting of the tetracycline repressor protein (TetR) and its 
specific DNA binding site, the tetracycline operator sequence (tetO). In the original system, 
TetR blocks transcription of resistance-mediating genes by binding to the tetO sequences. In 
the presence of tetracycline, TetR dissociates from tetO and gene transcription is induced. 
For optimized application in mammalian organisms and cell lines the synthetic Tet-Off 
(Gossen and Bujard, 1992) and Tet-On (Gossen et al., 1995) systems were developed. The 
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key component of the first established Tet-Off system is the tetracycline-controlled 
transactivator (tTA). This fusion protein consists of the DNA binding domain of the bacterial 
TetR and the transcriptional activation domain of herpes simplex virus VP16 protein that 
allows interaction with the eukaryotic transcription machinery. The second component, the 
synthetic Tet-response element (TRE), consists of a fusion between a minimal CMV 
promoter and an array of seven tetO sequences. Because the Tet-Off system requires 
persistent administration of tetracycline or its derivative doxycycline (Dox) to suppress gene 
expression that my trigger undesirable side-effects, the Tet-On system was developed. This 
system is based on the reverse transactivator (rtTA) that contains four specific mutations in 
the TetR domain and therefore shows reverse binding properties. Thus, in the presence of 
Dox rtTA binds to the TRE and activates transcription of target genes. In the absence of Dox 
rtTA cannot bind to TRE and target gene expression is abolished (Fig. 9).  
 
 
Fig. 9. Schematic representation of the Tetracycline inducible system (Tet-On). The Tet-On 
system consists of the reverse tetracycline-controlled transactivator (rtTA) and the Tet-responsive 
element (TRE). If tetracycline is absent, target gene expression is abolished. In contrast, binding of 
tetracycline to rtTA causes a conformational change in rtTA leading to association with DNA and 
activation of gene transcription. P promoter, LTR long terminal repeats. 
 
A major bottle-neck of tetracycline-inducible (Tet) systems is the basal transcriptional activity 
in the off-state of the system. This leakiness is due to intrinsic residual activity of the minimal 
CMV promoter and low residual affinity of the reverse tetracycline transactivator (rtTA) to the 
tetracycline response element (TRE) in the absence of Tet. To circumvent these limitations, 
improved rtTA proteins and several redesigned and optimized TRE sequences have been 
developed (Baron et al., 2000; Urlinger et al., 2000) that exhibit improved sensitivity to Tet 
and lower basal activity in the off-state. Despite the generation of novel Tet-components the 
efficacy of tetracycline-dependent gene expression is strongly dependent on the cell type 
and the vector systems harboring the TRE and the rtTA. In particular, efficient Tet-
regulatable expression vectors for the use in hematopoietic cells should be developed. 
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1.5 Objectives 
The tight control of the duration and magnitude of JAK2/STAT5 signal transduction through 
the EpoR is crucial for the controlled balance of erythrocyte production. In the past years, a 
large number of factors regulating Epo-induced JAK2/STAT5 signaling have been identified. 
However, the importance and complex roles of these negative regulators in controlling the 
strength and dynamic behavior of the signal outcome are poorly understood. Moreover, little 
is known about differences in regulatory mechanisms of EpoR-signaling between primary 
erythroid progenitors at the CFU-E stage and cell lines that are frequently used as model 
system to study the Epo-induced JAK2/STAT5 pathway. Furthermore, key properties of the 
pathway that facilitate rapid information processing and sensitivity such as signal 
amplification are largely unknown in Epo-induced JAK/STAT signaling. 
The goal of this work was to establish a mathematical pathway model of Epo-induced 
JAK2/STAT5 signaling in primary erythroid progenitor cells based on quantitative, time-
resolved experimental data to identify the critical negative feedback regulators that attenuate 
EpoR signaling. Employing analytic tools of the mathematical model, the distinct temporal 
characteristics of negative regulators modulating the signal strength and duration of 
JAK2/STAT5 signaling should be elucidated. Additionally, this work aimed at understanding, 
how signaling dynamics are linked to the regulation of survival of erythroid progenitor cells. 
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2 Results 
2.1 Mathematical model to study signal amplification in the JAK2/STAT5 pathway 
The JAK2/STAT5 pathway rapidly transmits Epo signals from the cell membrane into the 
nucleus to activate gene transcription. To investigate key properties of the pathway allowing 
signal amplification between the EpoR and STAT5 and sensitivity of the system to different 
Epo concentrations, a data-based mathematical model was established. Computational 
modeling was performed in collaboration with Julio Vera (University of Rostock). The 
mathematical model representing the Epo-induced JAK/STAT5 pathway (Fig. 10a) was 
implemented using two different strategies that were compared in this study: (i) a 
conventional ordinary differential equation (ODE) model based on mass action kinetics and 
(ii) a power-law formulation that allows non-integer kinetic orders of the reactions (Vera, 
Bachmann et al., 2008). The model topology was based on a previous data-based 
mathematical model of the JAK2/STAT5 pathway that revealed nucleocytoplasmic cycling as 
an essential building principle of this cascade (Swameye et al., 2003). In order to relate Epo 
stimuli to STAT5 signaling responses, Epo was used as input function. Receptor dynamics 
were simplified by EpoR/JAK2 complexes that are deactivated by phosphatases or 
internalization. STAT5 was considered to have three different states: non-activated STAT5 in 
the cytosol, activated STAT5 in the cytosol and activated STAT5 in the nucleus. (see – 
Appendix 6.1 Ordinary differential equations model to study JAK2/STAT5 amplification). 
 
 
 
Fig. 10. Calibrated JAK2/STAT5 pathway model in BaF3-EpoR cells. (a) Schematic representation 
of the JAK2/STAT5 model. Upon Epo binding, the pre-associated EpoR-JAK2 (EJ) complex is 
phosphorylated. The activated EpoR-JAK (pEpJ) complex recruits STAT5 (S) that is phosphorylated. 
STAT5 dimers (2pS) translocate to the nucleus to activate transcription (2pSnc). After deactivation 
STAT5 returns into the cytosol. (b) Model calibration with experimental data. BaF3-EpoR cells were 
stimulated with 5 U/ml Epo and cellular lysates were subjected to immunoprecipitation with antibodies 
against EpoR and STAT5 and subsequently analyzed by quantitative immunoblotting. Data obtained 
from two experiments (1: crosses; 2: circles) are compared with the solution of the model trajectories 
(lines) (Vera, Bachmann et al., 2008)  
a b 
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To calibrate the mathematical model, time series of EpoR and STAT5 phosphorylation 
dynamics in BaF3-EpoR cells were generated by quantitative immunoblotting (Fig. 10b). 
When comparing the conventional model with fixed integer kinetic orders and models with an 
increasing number of variable non-integer kinetic orders, the best compromise between 
accurate data fitting and a suitable number of estimated parameters was observed for the 
model with fixed integer kinetic orders. This suggests that power law formulations are not 
required for describing the data. After parameter estimation, the calibrated model was 
employed to investigate the responsiveness of the system. Therefore, the amount of 
phosphorylated STAT5 in the nucleus was simulated for different Epo concentrations.  
Fig. 11 shows the computed response of phosphorylated STAT5 values related to 
logarithmically scaled Epo concentrations.  
 
 
 
Fig. 11. Responsiveness of JAK2/STAT5 
signaling for different Epo concentrations. 
The response of the system is represented by 
steady-state values of pSTAT5 in the nucleus 
and analyzed for different values of constant Epo 
concentrations ranging from 10-8 U/ml to 50 
U/ml. The physiological serum concentration of 
Epo, (7.9×10-3 U/ml: long-dashed line) and the 
concentration of Epo used in the experiments (5 
U/ml: short-dashed line) are indicated. DpSnc,ss: 
dimerized phosphorylated STAT5 in the nucleus, 
Eposs: Epo (Vera, Bachmann et al., 2008). 
 
The sigmoidal behavior of the signal response demonstrates that the system is maximally 
sensitive to changes of Epo concentrations in the interval of 10-3-10-1 U/ml. Interestingly, this 
range includes the physiological serum concentration in mice of approximately 7.9×10-3 U/ml 
Epo (Noe et al., 1999). For stimuli smaller than 10-4 U/ml the system is not significantly 
activated while upon stimuli beyond 5 U/ml the system becomes saturated to any further 
increase of the stimulus. This behavior has been previously described as a typical feature of 
amplifying signal transduction pathways (Barkai and Leibler, 1997). Furthermore, to quantify 
the ability of the system to amplify the signal, the logarithmic amplification was defined as the 
logarithm of the ratio between the total amount of activated STAT5 in the nucleus and the 
activated EpoR (see – Appendix 6.1 Ordinary differential equations model to study 
JAK2/STAT5 amplification). The amplification factor showed maximal increase of 
amplification in the interval 10-4-10-1 U/ml of Epo which also includes the physiological value 
of Epo. 
In conclusion, the mathematical model showed that the JAK2/STAT5 system acts as efficient 
amplifier. The sensitivity for input signals is maximal for the range of physiological values and 
reaches saturation for very intense Epo stimuli.  
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2.2 Genome-wide analysis of Epo-induced transcriptional regulators 
The activation of JAK2/STAT5 signaling is counterbalanced by signal terminating events that 
regulate signal duration and magnitude. To obtain a comprehensive overview of Epo-
mediated induction of negative feedback regulators genome-wide expression profiling was 
performed. Exogenous expression of the EpoR in the factor-dependent murine pro-B cell line 
BaF3-EpoR is a well established tool to study Epo-dependent JAK2/STAT5 signaling. 
However, little is known about differences in the regulation of the signaling pathway between 
this cell line and primary erythroid progenitor cells at the CFU-E stage that endogenously 
express the EpoR and are strictly Epo-dependent for proliferation, survival and 
differentiation. To compare negative feedback regulation in BaF3-EpoR and CFU-E cells 
time-resolved genome wide expression profiling was performed for both cell types. CFU-E 
cells isolated from murine fetal livers were stimulated with 0.5 U/ml Epo for 24 h and total 
RNA was extracted at timepoints 0, 1, 2, 3, 4, 5, 6, 7, 8, 14, 19, 24 h. Control cells were left 
unstimulated and RNA was isolated every hour between 0 and 8 h. This shortened time 
frame was chosen since CFU-E cells are Epo-dependent and undergo apoptosis beyond 8 h 
without stimulation. BaF3-EpoR cells were starved and either stimulated with 0.5 U/ml Epo or 
left untreated for 24 h and total RNA was extracted at timepoints 0, 1, 2, 3, 4, 5, 6, 7, 8, 20, 
24 h. Processing of samples and data analysis was performed in collaboration with Norbert 
Gretz (University Hospital of Heidelberg in Mannheim) and Hauke Busch (University of 
Heidelberg). For hybridization, the GeneChip Mouse Genome 430 2.0 Array (Affymetrix) was 
used that comprises 45,100 probe sets representing 20,700 genes. Data analysis was 
performed by calculating the logarithmic fold change with respect to gene expression at 0 h.  
In order to gain systematic insights into negative feedback regulation the genes encoding 
known negative regulators of JAK/STAT signaling were compiled. Based on literature 
information these genes were grouped into the following protein families: SOCS proteins, 
protein tyrosine phosphatases and PIAS proteins. The expression profiles of CFU-E and 
BaF3-EpoR cells without stimulation showed no up- or downregulation of mRNA levels of the 
selected negative regulators demonstrating that up- or downregulation in stimulated cells is 
Epo-specific. In CFU-E cells the mRNA levels of the two SOCS proteins CIS and SOCS3 
were rapidly upregulated within one hour after stimulation and remained at a constant high 
level within 24 h of observation (Fig. 12a). These results were validated with qPCR and the 
same kinetics with a rapid induction were observed (see – Appendix 6.2 Validation of time-
resolved mRNA induction of SOCS3 and CIS). SOCS1, which has also been reported as 
negative feedback regulator in EpoR signaling showed no significant modulation in CFU-E 
cells. In BaF3-EpoR cells (Fig. 12b) various SOCS proteins showed rapid induction after 
stimulation with Epo including CIS, SOCS1, SOCS3 and SOCS6. 
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Fig. 12. Time-resolved expression profiling (Affymetrix microarray) of Epo-induced negative 
regulators in CFU-E cells and BaF3-EpoR cells. Log2-fold change of mRNA levels relative to 
timepoint t = 0 min after stimulation with Epo in (a) CFU-E cells and (b) BaF3-EpoR cells. Raw data 
were processed using the R environment together with the Bioconductor toolbox. The logarithmic 
gene fold expression was calculated with respect to the gene expression at 0 h. 
 
However, the induction of these transcripts was only transient and declined to basal or even 
below basal level after 3-4 h. The time-resolved expression profiles of PIAS proteins and 
phosphatases showed only little Epo-dependent regulation of transcript levels over the entire 
period of observation in the two cell types. Solely the mRNA level of tyrosine phosphatase 
SHP-1 was weakly downmodulated upon stimulation with Epo. The half-life of SH2-domain 
containing phosphatases, however, has been estimated to range between 18-20 h (Siewert 
et al., 1999) suggesting that transcriptional regulation of SHP-1 does not significantly affect 
SHP-1 protein level in the first hours after Epo stimulation. 
In summary, the microarray analysis indicated an Epo-dependent upregulation of CIS and 
SOCS3 in CFU-E cells. Their mRNA levels showed a rapid and strong induction suggesting 
an important role of the two proteins in the regulation of JAK2/STAT5 signaling in primary 
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erythroid cells. Furthermore, both transcripts were most strongly upregulated in BaF3-EpoR 
in comparison to other SOCS genes. Therefore, the following studies of transcriptional 
feedback regulation in JAK2/STAT5 signaling were focused on these two proteins. 
2.3 Generation of quantitative and time-resolved data on JAK2/STAT5 signaling 
2.3.1 Quantification of JAK2/STAT5 pathway components and negative regulators 
Based on genome-wide transcriptional profiling the two SOCS proteins CIS and SOCS3 
were identified as putative negative regulators of Epo-induced signaling which is in line with 
other studies indicating the involvement of SOCS proteins in this pathway. Additionally, the 
tyrosine phosphatase SHP1 that is constitutively expressed in hematopoietic cells was 
proposed in previous studies as a major negative regulator of Epo-induced signaling 
(Klingmüller, 1997). To dissect the complex roles of these three proteins that function by 
different mechanisms to attenuate JAK2/STAT5 signaling, a mathematical modelling 
approach provides useful tools that may help to gain deeper insight into negative feedback 
regulation of this pathway. However, establishing a mathematical model requires quantitative 
information about the protein species involved. 
In order to analyze stoichiometric ratios and start values of the signaling components that are 
important for the mathematical model, the negative regulators were quantified at the protein 
level. Since CIS and SOCS3 are not constitutively expressed, cells were stimulated with 5 
U/ml Epo and protein levels were determined at maximum activation (t = 120 min). SHP-1 
levels remained constant over time (Fig. 14) and were therefore estimated in untreated cells. 
To quantify endogenous protein levels, calibration curves of recombinant proteins were used 
in combination with quantitative immunoblotting (Schilling et al., 2005b). Therefore, 
recombinant proteins (calibrators) consisting of the protein of interest tagged with either 
streptavidine binding peptide (SBP) or glutathione S-transferase (GST) for purification were 
generated in E.coli. The concentration of these calibrators was determined by means of a 
known BSA standard. To determine endogenous protein levels, serial dilutions of the 
respective calibrators were added to cellular lysates prior to immunoprecipitation. After 
quantification of immunoblotting signals by chemiluminescence detection, calibration curves 
were calculated from dilution series. Based on the assumption that antibodies used for 
immunoprecipitation and immunoblotting possess the same affinity for the recombinant and 
the endogenous protein species, absolute endogenous protein concentrations could be 
estimated. Fig. 13 shows the quantifications of the negative regulators CIS, SHP-1 and 
SOCS3 in BaF3-EpoR and CFU-E cells that were analyzed by applying the recombinant 
proteins SBP-CIS, SBP-SOCS3 and GST-SHP-1.  
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Fig. 13. Protein quantification of negative regulators of the JAK2/STAT5 pathway. Endogenous 
protein levels of SHP-1, CIS and SOCS3 were estimated in cellular lysates of BaF3-EpoR and CFU-E 
cells by means of dilution series (n=3) of added recombinant calibrator proteins SBP-CIS, GST-SHP-
1 and SBP-SOCS, respectively. For quantification of CIS and SOCS3, cells were stimulated with 5 
U/ml Epo for 2 h and subsequently lysed. Proteins were immunoprecipitated and analyzed by 
quantitative immunoblotting based on chemiluminescence detection. Dilution series of recombinant 
proteins were plotted with respective linear regression functions (solid lines) (a) for SHP-1 in BaF3-
EpoR (3×105) and in CFU-E (1×107) cells, (b) for CIS in BaF3-EpoR (1×107) and CFU-E (1×107) cells, 
and (c) SOCS3 in BaF3-EpoR (1×107) and CFU-E (5×106) cells. Molecules per cell were calculated 
by means of the respective regression function. Bar plots show estimated molecules per cell of SHP-
1, CIS and SOCS3 in BaF3-EpoR cells (black bars) and CFU-E cells (white bars). 
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For an overview of the results see Table 1. The endogenous levels of CIS were observed to 
be within the same range in BaF3-EpoR of approximately 8,600 molecules per cell and in 
CFU-E cells of 6,500 molecules per cell. Similarly, the levels of SOCS3 in BaF3-EpoR cells 
of approximately 1,300 molecules per cell were comparable with levels in CFU-E cells of 
2,600 molecules per cell.  
 
 BaF3-EpoR CFU-E 
 molecules/cell concentration* molecules/cell concentration* 
EpoR on surface 15,700 ± 1300  21.6 ± 13.3 /µm
2 ~ 1000 32.3 ± 6.7 /µm2 
JAK2 13,700 ± 3,300 16.3 ± 4.0 nM 23,700 ± 13,000 98.4 ± 54.0 nM 
Stat5 175,000 ± 75,000 207.6 ± 89.0 nM 20,000 ± 10,000 83.0 ± 41.5 nM 
SHP-1 450,000 ± 90,000 385.5 ± 90.0 nM 8,500 ± 1,700 27.0 ± 6.2 nM 
CIS 8,600 ± 700 7.1 ± 2.4 nM 6,500 ± 700 24.9 ± 8.3 nM 
SOCS3 1,300 ± 500 1.78 ± 0.7 nM 2,600 ± 900 10.39 ± 4.3 nM 
 
Table 1. Molecules per cell of JAK2/STAT5 pathway components estimated in BaF3-EpoR and 
CFU-E cells. Protein numbers were estimated as described. To calculate the concentrations different 
volumes and surface areas were considered for BaF3-EpoR (cytoplasm: 1400 µm3, nucleus: 450 µm3, 
surface area: 729 µm2) and CFU-E cells (cytoplasm: 400 µm3, nucleus; 275 µm3, surface area: 372 
729 µm2). Numbers of EpoR, JAK2, STAT5 were kindly provided by Marcel Schilling and Andrea C. 
Pfeifer (DKFZ, Heidelberg). Molecules per cell for EpoR on the surface of CFU-E cells was reported 
previously (D'Andrea and Zon, 1990). *In the case of EpoR the density on the surface is displayed 
instead of the concentration. 
 
Interestingly, the endogenous level of SHP-1 in BaF3-EpoR cells with 450,000 molecules per 
cell was estimated to be more than 50-fold higher compared to the level in the primary cells 
with approximately 8,500 molecules per cell. The results of the quantifications are 
summarized in Table 1, including endogenous levels of the EpoR, JAK2 and STAT5 (kindly 
provided by Andrea C. Pfeifer and Marcel Schilling, DKFZ Heidelberg).  
The comparison of JAK2 and STAT5 levels revealed also remarkable differences in both cell 
types. In particular, the numbers of STAT5 in BaF3 cells are almost 10-fold higher than in 
CFU-E cells. By estimating the absolute protein concentrations of SHP-1, CIS, SOCS3, 
STAT5 and JAK2 parameter ranges of initial values could be defined for each of the 
measured protein species in the mathematical model of the JAK2/STAT5 pathway in CFU-E 
cells (see Results - 2.5 Implementation of dynamic JAK2/STAT5 pathway model). 
2.3.2 Cell type-specific activation profile of the Epo-induced JAK2/STAT5 pathway 
When studying the dynamic behavior of signal transduction pathways by mathematical 
modeling, the major prerequisite is the availability of reliable quantitative and time-resolved 
data. Thus, a standardized protocol was established to measure time-course experiments of 
JAK2/STAT5 pathway activation in BaF3-EpoR and CFU-E cells that ensures experimental 
reproducibility. Preliminary tests and dose-response experiments revealed that a starvation 
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time of 4 hours in BaF3-EpoR and 2 hours in CFU-E cells as well as a dose of 5 U/ml Epo is 
appropriate for maximal signal activation. Hence, these conditions were used in all time-
course experiments.  
The activation kinetics of EpoR, JAK2 and STAT5 phosphorylation, the level of total proteins 
as well as the levels of SHP-1 were determined by immunoprecipitation and subsequent 
quantitative immunoblotting in both BaF3-EpoR and CFU-E cells. As CIS was induced more 
strongly at protein level compared to SOCS3 in both cell-types, only CIS expression was 
recorded. For computational data processing, constant amounts of recombinant calibrator 
proteins were added to cellular lysates prior to immunoprecipitation. SDS-PAGE samples 
were loaded in a randomized, non-chronological order (Schilling et al., 2005a). 
Representative examples of original immunoblotting data are depicted (Fig. 14). Because of 
the limited availability of primary CFU-E cells, the time-course consisted of only 14 time-
points while in BaF3-EpoR cells 18 timepoints were recorded.  
As the time-course data demonstrated, the initial activation dynamics of EpoR, JAK2 and 
STAT5 in BaF3-EpoR and CFU-E (Fig. 15) cells resemble each other in respect to the time-
resolution of sample intervals. Induction of phosphorylation occurred within the first minutes 
upon Epo stimulation and all three proteins showed maximal peak activation at 
approximately 10 min followed by a sharp decline. Following pathway activation, expression 
of the negative regulatory protein CIS was induced after 30-60 min in both cell types. The 
tyrosine phosphatase SHP-1 is constitutively expressed and remained constant over the 
entire period of observation. However, after approximately 2 h of Epo stimulation, the 
phosphorylation kinetics of JAK2/STAT5 pathway components showed significant differences 
between the two cell types. In BaF3-EpoR cells, the activation curves of EpoR and STAT5 
returned to basal level, whereas in primary cells a residual steady-state phosphorylation level 
remained over 4 h of observation. Furthermore, the expression profile of the negative 
regulatory protein CIS differed in the two cell types. CIS expression in BaF3-EpoR cells 
reached a transient maximum after approximately 2 h of Epo stimulation followed by a 
decline to basal levels. In contrast, in primary cells CIS expression reached a sustained 
plateau within 4 h. Finally, the levels of total proteins showed remarkable differences. While 
JAK2 and EpoR remained constant in CFU-E cells, their levels in BaF3-EpoR cells 
decreased during the time of observation. 
Taken together, the discrepancies in the kinetic behavior of the JAK2/STAT5 pathway 
between BaF3-EpoR and CFU-E cells suggested fundamental differences in the deactivation 
processes and further emphasized the importance of studies that compare the mechanisms 
of negative regulation of JAK2/STAT5 signaling in cell lines versus primary cells. 
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Fig. 14. Immunoblotting data of time-course experiments in BaF3-EpoR and CFU-E cells. 
Densely sampled time-course in Epo-induced (a) BaF3-EpoR and (b) CFU-E cells. Either BaF3-EpoR 
(1×107) or CFU-E cells (5×106) were stimulated with 5 U/ml Epo. At the indicated time points, cellular 
lysates were subjected to immunoprecipitation with antibodies against JAK2, EpoR, STAT5 and CIS 
and subsequently analyzed by quantitative immunoblotting based on chemiluminescence detection. 
All experiments were performed at least in triplicates and one representative example is shown. 
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Fig. 15. Time series of Epo-induced JAK2/STAT5 pathway activation in BaF3-EpoR and CFU-E 
cells. Starved (a) BaF3-EpoR cells (1×107) or (b) CFU-E (5×106) were stimulated with 5 U/ml Epo and 
analyzed for relative levels of phosphorylated JAK2, EpoR and STAT5 as well as for relative expression 
levels of total proteins CIS, SHP-1, EpoR, JAK2 and STAT5. Data generated in BaF3-EpoR (triangles) or 
CFU-E (circles) cells were processed using GelInspector software and plotted with splines (solid lines). 
Time-course experiments were performed three times and a representative analysis is shown. 
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2.4 Targeted perturbation of negative feedback components 
To gain insight into the potential role of the three negative feedback regulators SHP-1, CIS 
and SOCS3 in the cell line BaF3-EpoR and primary CFU-E cells, two strategies were 
employed. The Tet-inducible system was established to facilitate inducible dose-dependent 
overexpression of SHP-1 in BaF3-EpoR cells. By employing this technique the 
consequences of temporally controlled upregulated negative feedback loops on the dynamic 
behavior of the JAK2/STAT5 signaling pathway in BaF3-EpoR cells could be investigated. 
However, for CFU-E cells, the Tet-system is not applicable since these primary cells start to 
differentiate after approximately one day in culture. In the second strategy, the general 
inhibitor of transcription, actinomycin D, was used to block expression of induced 
transcriptional regulators. 
2.4.1 Establishing the Tet-inducible system in BaF3 cells 
To establish the Tet-system in BaF3 cells, the improved transactivator variant rtTA-M2 
(Urlinger et al., 2000) as well as two different tet-response elements (TREs) have been 
employed. The first one, designated as TRE-L, contained the original heptamerized Tet-
operator sequence Ptet-1 with the CMV minimal promoter. The second one, denoted as TRE-
T in this study, consists of a modified Tet-operator sequence and a shortened CMV promoter 
and was proposed to display tight control of gene expression with significantly less 
background activity than the original system (H. Bujard, ZMBH). 
Besides the Tet-system components, an appropriate retroviral vector system is essential to 
achieve maximal induction rates and low background levels in hematopoietic cells which are 
difficult to transfect. Therefore, various retroviral vectors were tested and the two most 
efficient were selected. For the delivery of the gene of interest under the control of the TRE, 
a self-inactivating (SIN) retroviral vector (pMOWSIN) was used. This SIN-vector lacked the 
promoter and enhancer region of the U3 sequence in the 3’proviral longterminal repeats 
(LTRs) and thus prevented potential cross talk between the strong viral promoter and the 
inducible TRE that otherwise may cause increased background expression of the gene of 
interest. The rtTA was delivered by a second retroviral vector pMOWS (Ketteler et al., 2002) 
that was identified to produce the highest level of transgene expression in BaF3 cells.  
In order to establish and evaluate the Tet-system in BaF3 cells, green fluorescent protein 
(GFP) was used as a reporter in induction assays that allows for detection not only by 
immunoblotting but also by flow cytometric analysis. BaF3 cells were co-transduced with 
both vectors and induced with increasing amounts of Dox ranging from 1 to 5000 ng/ml to 
compare the two different TRE variants, TRE-L and TRE-T. Relative expression levels of 
GFP were monitored by flow cytometric analysis as well as by immunoblotting of cellular 
lysates 24 h hours after Dox induction (Fig. 16).  
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Fig. 16. Dose-dependent expression of GFP by the Tet-inducible system in BaF3 cells. BaF3 
cells co-transduced with pMOWS-rtTA and pMOWSIN-TRE-GFP (variant TRE-T or TRE-L) were 
induced with increasing concentrations of Dox for 24 h. (a) Expression of GFP was subsequently 
determined in cellular lysates of 1×106 BaF3 cells by immunoblotting based on chemiluminescence 
detection. Quantification of immunoblot signals was plotted versus Dox concentrations (triangles) with 
a saturation regression function. Bars represent maximal fold induction of GFP with 5000 ng/ml Dox 
compared to background expression level with 0 ng/ml Dox. (b) A corresponding flow cytometry 
analysis was performed. The overlay histogram depicts four representative results of different 
doxycycline concentrations. The mean fluorescence was plotted versus Dox concentrations (triangles) 
with a saturation regression function. Bars represent maximal fold induction of GFP with 5000 ng/ml 
Dox compared to background expression level with 0 ng/ml Dox. 
 
Quantification of GFP expression demonstrated that the system is particularly sensitive to 
low Dox concentrations between 5 and 500 ng/ml. In this range, the expression level of GFP 
followed the increasing concentrations of Dox almost linearly before saturation was reached 
at approximately 1000 ng/ml Dox. Interestingly, by comparing the flow cytometry analysis of 
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the two TRE variants, TRE-T showed significantly lower background activity at 0 ng/ml Dox 
which is in line with its proposed optimized efficacy. On the other hand, GFP expression 
under the control of the TRE-L variant achieved a remarkable higher range of overexpression 
up to 35-fold whereas the TRE-T variant only reached up to 20-fold GFP overexpression at 
highest Dox concentrations. Thus, exploiting the possibilities of the two TRE-variants, either 
tight control or high induction rates can be attained in BaF3 cells according to individual 
requirements.  
2.4.2 Tet-inducible overexpression of SHP-1 in BaF3-EpoR cells 
Next, the Tet-inducible expression system was used to overexpress SHP-1 in BaF3-EpoR 
cells and investigate the consequences on the dynamic behavior of the JAK2/STAT5 
signaling pathway. Preliminary tests revealed that an induction of 8 h with Dox prior to Epo 
stimulation is sufficient to allow for high expression rates but avoid potential toxic artefacts of 
constitutively overexpressed negative regulators. In order to monitor the dynamic behavior of 
the JAK2/STAT5 signaling pathway in cells with upregulated SHP-1 levels, Dox-induced 
BaF3-EpoR cells were stimulated with 5 U/ml Epo and the kinetics of EpoR, JAK2 and 
STAT5 phosphorylation were determined by immunoprecipitation and subsequent 
quantitative immunoblotting based on chemiluminescence detection (Fig. 17). Surprisingly, 
the phosphorylation levels of EpoR, was altered only marginally. The phosphorylation of 
JAK2 which is suggested to be a substrate of SHP-1 showed no difference compared to the 
control while STAT5 phosphorylation was reduced slightly indicating that the effects taking 
place at the receptor level are transmitted to STAT5 level. 
Taken together, the overexpression of SHP-1 had only little impact on the phosphorylation 
levels of the JAK2/STAT5 pathway components. This observation may be explained by the 
high endogenous expression level of SHP-1 in BaF3-EpoR cells and the comparable low 
overexpression level of only 2-fold. Moreover, previous studies reported that SHP-1 is not 
constitutively active but requires binding to a phosphorylated tyrosine residue i.e. on the 
EpoR to be activated (Pao et al., 2007b). Because of the limited numbers of EpoR in the 
cells, the activation of SHP-1 may reach saturation that renders further upregulation of SHP-
1 levels ineffective. 
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Fig. 17. Time series of Epo-induced JAK2/STAT5 pathway activation in BaF3-EpoR cells 
overexpressing SHP-1. BaF3-EpoR cells co-transduced with pMOWS-rtTA and pMOWS-TRE-L-
SHP-1 were induced with 2 µg/ml Dox (green) or without addition (black) for 8 h prior to stimulation 
with Epo. Cellular lysates of 1×107 BaF3-EpoR cells were analyzed for relative levels of 
phosphorylated JAK2, EpoR, STAT5 and relative expression level of total proteins CIS, EpoR, JAK2, 
STAT5 and SHP1 upon stimulation with 5 U/ml Epo. At the indicated time points, stimulated cells 
were lysed and proteins were analyzed by immunoprecipitation and subsequent quantitative 
immunoblotting. Data (triangles) was processed using GelInspector software and plotted with 
smoothing splines (solid lines). Time-course experiments were performed three times and a 
representative analysis is shown. 
 
2.4.3 Different impact of actinomycin D-mediated inhibition 
Next, the generic inhibitor actinomycin D was used to inhibit transcription and observe the 
consequences on the dynamic behavior of JAK2/STAT5 signaling in BaF3-EpoR cells and 
primary CFU-E cells. Therefore, cells were treated with 1 µg/ml actinomycin for 10 min and 
the dynamic behavior of JAK2, EpoR and STAT5 activation was monitored as described 
before (see – Results 2.4 Kinetic activation profile of JAK2/STAT5 signaling). The original 
immunoblotting data are depicted in Fig. 18. 
As control for the effectiveness of actinomycin D treatment on transcription, the kinetics of 
CIS expression in actinomycin D treated cells were compared to control cells. As 
demonstrated by the immunoblot of CIS in CFU-E and BaF3-EpoR cells (Fig. 18) 1 µg/ml 
actinomycin D was sufficient to completely block expression in both cells types. Interestingly, 
in BaF3-EpoR cells the kinetics of phosphorylation of EpoR, JAK2 and STAT5 between 
actinomycin D-treated cells and control cells showed no significant differences (Fig. 19a). 
These results indicate that induced transcriptional regulators seem to play no major role in 
attenuating signal transduction in BaF3-EpoR cells.  
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Fig. 18. Immunoblotting data of time-course experiments in untreated and in actinomycin D-
treated BaF3-EpoR and CFU-E cells. (a) BaF3-EpoR or (b) CFU-E cells were treated with either 1 
µg/ml actinomycin D or with vehicle (0.1 % dimethylsulfoxide) alone for 10 min. Subsequently, BaF3-
EpoR (1×107) or CFU-E cells (5×106) were stimulated with 5 U/ml Epo. At the indicated time points 
and cellular lysates were subjected to immunoprecipitation with antibodies against JAK2, EpoR, 
STAT5 and CIS and analyzed by quantitative immunoblotting based on chemiluminescence detection. 
All experiments were performed at least in triplicates and one representative example is shown.  
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Fig. 19. Time series of Epo-induced JAK2/STAT5 pathway activation in untreated and in 
actinomycin D-treated BaF3-EpoR cells and CFU-E cells. (a) BaF3-EpoR or (b) CFU-E cells were 
treated with 1 µg/ml actinomycin D (blue) or with vehicle (0.1 % dimethylsulfoxide) alone (black) for 10 
min. BaF3-EpoR or CFU-E cells were induced with 5 U/ml Epo and analyzed for relative levels of 
phosphorylated JAK2, EpoR, STAT5 and relative expression level of total proteins CIS, EpoR, JAK2 
and STAT5 at the indicated time points. Generated data in BaF3-EpoR (triangles) was processed 
using GelInspector software and plotted with smoothing splines (solid lines). Time-course experiments 
were performed three times and a representative analysis is shown. 
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In CFU-E cells, however, the long-term phosphorylation level of STAT5 was significantly 
elevated in actinomycin D-treated cells. Hence, this result suggested a mechanism that 
involves induction of transcriptional regulators to control the long-term steady-state level of 
STAT5. The kinetics of EpoR and JAK2 differed only marginally from the control, indicating 
that downregulation of these species is predominantly regulated by other mechanisms. 
In summary, the time-course experiments with actinomycin treatment demonstrated that the 
role of transcriptional regulators in the JAK2/STAT5 pathway differ in BaF3-EpoR cells and 
primary CFU-E cells. Thus, these observations underscore the importance of studying the 
effects of negative feedback loops in the relevant cellular context. For a deeper 
understanding of the situation in vivo it is essential to investigate the processes in primary 
CFU-E cells. 
2.5 Implementation of dynamic JAK2/STAT5 pathway model in CFU-E cells 
The three proteins SHP-1, SOCS3 and CIS have been identified in this work as putative 
negative regulators of the Epo-induced JAK2/STAT5 pathway which is in line with previous 
reports. Because of their overlapping functions, a major question was how these proteins 
control the JAK2/STAT5 pathway in respect to temporal aspects and effectiveness of signal 
inhibition. Employing the analytical tools of a mathematical modeling approach by 
systematically combining biological knowledge with quantitative experimental data a deeper 
insight into the control of the JAK2/STAT5 pathway can be attained. In particular, a dynamic 
model enables the identification and evaluation of the most important reactions and proteins 
involved in controlling the output of the system which is difficult to observe with classical 
experimental techniques. 
In collaboration with Marcel Schilling (DKFZ, Heidelberg) and Andreas Raue (FDM, 
University of Freiburg) an ordinary differential equation (ODE) model of the Epo-induced 
JAK2/STAT5 pathway was implemented. All reactions of the network were modelled by 
mass-action kinetics or by Michaelis-Menten approximations. The general topology of the 
model was constructed based on prior biological knowledge and experimental data 
generated in this work. At first, a large model comprising all possible biological complexes 
and biochemical reactions was compiled. However, the major drawback of this very detailed 
model was the large number of free variables leading to unidentifiable parameters. Hence, in 
an iterative process the model was condensed by systematically abandoning short-lived 
protein-protein complexes and very rapid reactions that were proven not to be essential for 
describing the data as revealed by comparison of the model-data compliances. The final 
model comprised a total number of 13 variables and 17 parameters (Fig. 20). In this model, 
Epo was used as input function that directly triggered phosphorylation of JAK2. The activated 
kinase in turn mediated phosphorylation of the EpoR.  
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The tyrosine phosphatase SHP-1 has previously been shown to require binding to a 
phosphorylated tyrosine residue i.e. on the EpoR to activate phosphatase activity (Barford 
and Neel, 1998; Neel et al., 2003; Pei et al., 1996).  
 
 
 
 
Fig. 20. Schematic representation of the JAK2/STAT5 pathway model with negative feedback 
regulators in CFU-E cells. The model consists of 17 parameters and 13 variables. Reactions were 
modelled assuming mass-action (solid arrows). Enzyme catalysis (circle-headed lines), inhibition 
(bar-headed lines) and modifiers (diamond-headed lines) are represented. Protein expression is 
indicated as pointed-dashed line. Prefix p represents phosphorylated species, n nuclear species. 
Graphical notation was adapted using Cell Designer (Version 4.0.1.). 
 
 
Therefore, SHP-1 was considered to exist in two states in the model: one active and one 
inactive form. The transition of inactive to catalytically active SHP-1 is mediated by 
phosphorylated EpoR that reflects the recruitment to the specific phosphotyrosine residue. 
Because the number of EpoR is limited, activation of SHP-1 can reach saturation and thus 
was modelled by using a Michaelis-Menten approximation. The activated form of SHP-1 then 
can trigger dephosphorylation of JAK2 and the EpoR.  
Phosphorylation of STAT5 by JAK2 is mediated by recruiting STAT5 to phosphotyrosine 343 
and 401 of the EpoR cytoplasmic domain that functions as a scaffold (Barber et al., 2001; 
Gobert et al., 1996; Klingmüller et al., 1996). Thus, in the reaction of STAT5 activation both 
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proteins were included. Phosphorylated JAK2 was considered as enzyme and the 
phosphorylated EpoR as additional modifier. Dimerization of STAT5 is known to occur very 
rapidly after phosphorylation and could be neglected in the model. The phosphorylated and 
dimerized STAT5 shuttles into the nucleus and binds to consensus sequences of the DNA to 
activate gene transcription (Horvath, 2000). After a certain sojourn in the nucleus, 
dephosphorylated STAT5 translocates back into the cytoplasm to enter a new cycle of 
activation. This mechanism was revealed by a previous study that identified 
nucleocytoplasmic cycling of STAT5 as an important feature of the system to continuously 
monitor receptor activation (Swameye et al., 2003). The different forms of STAT5 were 
integrated in the model by three distinct variables: unphosphorylated STAT5 in the cytosol, 
phosphorylated STAT5 dimers in the cytosol and phosphorylated STAT5 dimers in the 
nucleus. Three parameters describe the transitions between these variables: STAT5 
activation, the import rate into the nucleus and the export rate back into the cytosol. 
The microarray analysis (Fig. 12) revealed that CIS and SOCS3 mRNA levels were rapidly 
and strongly upregulated in Epo-induced CFU-E cells (see 2.2 Genome-wide analysis of 
Epo-induced transcriptional regulators). Thus, both proteins were included into the 
mathematical model as transcriptional feedback regulators. Previously, SOCS3 has been 
proposed to bind via its SH2 domain to activated EpoR and JAK2 and to inhibit JAK2 activity 
by directly binding to the kinase activation loop via its KIR domain (Hortner et al., 2002; 
Sasaki et al., 1999; Sasaki et al., 2000). CIS was identified as negative regulator of 
JAK/STAT signaling by binding to phosphotyrosine 401 of the EpoR, thereby competing for 
receptor binding with STAT5 (Ketteler et al., 2003; Yoshimura et al., 1995). Another study 
indicated that CIS is involved in proteasome-mediated degradation of the EpoR (Verdier et 
al., 1998a). Hence, SOCS3 and CIS were included in the model at different levels of signal 
transmission: CIS was considered as inhibitor only of STAT5 and EpoR activation and the 
impact of CIS on STAT5 activation was thereby exclusively related to the EpoR-mediated 
contribution of the reaction. In contrast, SOCS3 additionally inhibited JAK2 activation and 
downstream signals. 
 
2.5.1 Generation of time-course data in CFU-E cells 
To determine the parameters of the JAK2/STAT5 pathway model, various stimulation time-
course experiments were performed in CFU-E cells monitoring the kinetics of several 
pathway components simultaneously by quantitative immunoblotting. Because CIS and 
SOCS3 have overlapping functions and thus are not structurally identifiable by the model, 
their role in negative regulation can only be dissected by perturbing the two proteins 
individually and observing the response of the system. Furthermore, to gain detailed 
information about the phosphatase also SHP-1 was altered directly. Consequently, five 
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different experimental conditions were selected to challenge the network and monitor the 
dynamic behavior experimentally upon Epo stimulation: (i) CFU-E cells (dense sampling and 
SOCS3 time-course) (ii) CFU-E cells treated with actinomycin D, (iii) CFU-E cells 
overexpressing CIS, (iv) CFU-E cells overexpressing SOCS3, (v) CFU-E cells 
overexpressing SHP-1. 
The generation of time-course data in Epo-stimulated CFU-E cells and additionally Epo-
stimulated CFU-E cells treated with actinomycin D has been described before (see - 2.3.2 
Cell type-specific activation profile of the Epo-induced JAK2/STAT5 pathway). To determine 
the kinetic of SOCS3 expression, time-course experiments were performed in Epo stimulated 
CFU-E cells (Fig. 21). The time-resolved expression profile of SOCS3 resembles the 
behavior of its mRNA kinetic. After approximately 30 min the endogenous protein level 
increases and reaches its maximum level at 120 min. Within the entire time of observation 
SOCS3 remains at this constant high level.  
 
 
 
Fig. 21. Time-course experiment of SOCS3 expression in CFU-E cells. Starved CFU-E cells 
(5×106) were stimulated with 5 U/ml Epo and analyzed for relative levels of total protein SOCS3. At 
the indicated time points cellular lysates were subjected to immunoprecipitation with anti-SOCS3 and 
subsequently analyzed by quantitative immunoblotting based on chemiluminescence detection. Time-
course experiments were performed in duplicates and a representative analysis is shown. 
 
 
In order to perform time-course experiments in CFU-E cells overexpressing SOCS3, CIS or 
SHP-1, freshly isolated primary erythroid progenitor cells were retrovirally transduced. The 
low transduction efficiency in primary erythroid cells yielded only 10-20% positive cells. 
These cells were sorted by the magnetic cell separation system (MACSselect, Miltenyi 
Biotec) and directly used for the experiment. Fig. 22 depicts representative examples of 
unprocessed immunoblotting data.  
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Fig. 22. Immunoblotting data of time-course experiments in CFU-E cells for multiple 
perturbation conditions. Freshly isolated CFU-E cells were retrovirally transduced with (a) SOCS3, 
(b) CIS or (c) SHP-1. After sorting of positive cells, CFU-E cells (5×106) were induced with 5 U/ml 
Epo. At the indicated time points cellular lysates were subjected to immunoprecipitation with 
antibodies against JAK2, EpoR, STAT5, CIS and SOCS3 and subsequently analyzed by quantitative 
immunoblotting based on chemiluminescence detection. All experiments were performed in at least 
duplicates and one representative example is shown. 
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Due to the limited availability of primary cells experiments consisted of only 4-6 timepoints. 
Overexpression of SOCS3 in CFU-E cells strongly inhibited the phosphorylation of JAK2, 
EpoR and STAT5 as well as the expression of CIS. CIS overexpression in CFU-E cells led to 
reduced activation of STAT5 and EpoR phosphorylation and caused decreased expression 
of SOCS3. In cells overexpressing SHP-1, the peak amplitude of EpoR and STAT5 activation 
were decreased considerably whereas CIS and JAK2 were reduced only marginally. 
2.5.2 Model calibration by multi-experiment fitting 
Parameter estimation was performed by multi-experiment fitting of all data sets (Fig. 14,Fig. 
18, Fig. 21, Fig. 22) simultaneously using the software PottersWheel (Maiwald and Timmer, 
2008). Six observables were defined for calibration of the mathematical model: 
phosphorylated EpoR, phosphorylated JAK2, STAT5 in the cytoplasm, phosphorylated 
STAT5 in the cytoplasm, CIS and SOCS3. The levels of total proteins of JAK2 and EpoR 
remained fairly constant over the entire period of observation and thus mass conservation 
was assumed for these proteins. The start values of the different species in the model were 
defined as described (see – 2.4 Quantifications of negative feedback regulators of the 
JAK2/STAT5 pathway). The concentrations of CIS and SOCS3 were set to zero at t = 0 min 
and the amounts determined at maximal activation t = 120 min were included in the model.  
Trajectories of the best fit are depicted (Fig. 23 - Fig. 25).  
 
 
Fig. 23. Model calibration by multi-experiment fitting (I): Time-course with dense sampling and 
SOCS3 in CFU-E cells. For generation of data refer to Fig. 14 and Fig. 21. Trajectories of the best fit 
are indicated by solid lines and experimental data are represented by black circles with standard 
deviations. Parameter estimation was performed simultaneously for five different data sets. χ2-values 
lower than N (number of data points) indicate accurate description of the data.  
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Fig. 24. Model calibration by multi-experiment fitting (II): Time-course in CFU-E cells treated with 
actinomycin D. For generation of the data refer to Fig. 18. Trajectories of the best fit are indicated by 
solid lines and experimental data are represented by black circles with standard deviations. Parameter 
estimation was performed simultaneously for five different data sets. χ2-values lower than N (number 
of data points) indicate accurate description of the data. 
 
The total χ2 = 241.82 that is defined as the model deviation from the data normalized to the 
measurement error, indicates an accurate description of the data in respect to the total 
number of N = 213 datapoints. For detailed information on parameter values refer to 
Appendix - 6.3 Ordinary differential equation model of the JAK2/STAT5 pathway in CFU-E 
cells. 
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Fig. 25. Model calibration by multi-experiment fitting (III): Time-course in CFU-E cells 
overexpressing SOCS3, CIS or SHP-1. For generation of data refer to Fig. 22. Trajectories of the 
best fit are indicated by solid lines and experimental data are represented by circles with standard 
deviations for (a) SOCS overexpression (orange), (b) CIS overexpression (blue) and (c) SHP-1 
overexpression (green). For visualization, simulated trajectories of control cells are indicated (dashed 
lines). Parameter estimation was performed simultaneously for five different data sets. χ2-values 
lower than N (number of data points) indicate accurate description of the data. 
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2.5.3 Identifiability of estimated parameters and confidence intervals 
For a good accuracy of model simulations, the estimated parameters are required to display 
small confidence intervals. Furthermore, to calculate the confidence intervals the model 
parameters have to be identifiable. Therefore, the estimated parameter values were 
investigated by a fit sequence analysis. Fits to experimental data were performed for 5000 
runs with varying initial guesses of parameters and the distribution of the calibrated 
parameter values of 4% of the best 5000 fits were plotted (see Appendix - 6.4 Identifiability 
analysis). Only three out of 17 parameters exhibited a large distribution of values indicating a 
non-identifiability. Detailed scatter plots of parameter dependencies revealed a strong 
correlation between these three parameters. The fixation of one of the three parameters 
resulted in a narrowed relative distribution of all parameters below 35% and thus all 
parameters could be defined as identifiable. Next, point-wise confidence intervals (68%) on 
the estimated parameter values were calculated. As represented in Fig. 26 sufficiently small 
confidence intervals were found for all parameters demonstrating good accuracy of model 
predictions. 
 
 
 
Fig. 26. Point-wise 1σ confidence intervals for estimated parameters. The best fit with smallest 
total χ2 = 241.82 was used to calculate the confidence intervals of all estimated parameters. In 
collaboration with Andreas Raue (University of Freiburg). 
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2.6 Control analysis of the JAK2/STAT5 pathway 
2.6.1 Effects of altered SHP-1, SOCS3 and CIS levels on JAK2/STAT5 signaling 
Statistical validation demonstrated a good model-data-compliance and adequate confidence 
intervals. Therefore, the calibrated model could be employed to investigate the impact of the 
negative feedback regulators SHP-1, SOCS3 and CIS on the kinetic behavior of the 
JAK2/STAT5 pathway. To address the question to what extent the magnitude as well as the 
duration of signaling are controlled by the phosphatase and the two SOCS proteins 
simulations with perturbed parameters controlling SHP-1, SOCS3 or CIS levels were 
performed (Fig. 27). 
The initial value of SHP-1 was logarithmically incremented in 5 steps to 10-fold or decreased 
in 5 steps to 0.1-fold expression. Simulations of the kinetic behavior of phosphorylated EpoR, 
JAK2 and STAT5 showed a strong influence of SHP-1 on the peak amplitude and signal 
duration (Fig. 27a). Interestingly, a high expression level of SHP-1 had only small effects on 
the signal intensity, whereas downregulation of the SHP-1 level strongly increased the 
duration. All signaling molecules were similar sensitive towards changes of SHP-1 levels. 
Parameters controlling SOCS3 and CIS expression were varied as described above for SHP-
1 to compare the effect of perturbed SOCS proteins on the pathway components (Fig. 
27b,c). Simulations showed that the influence of SOCS3 and CIS concentrated on the long-
term steady-state level of the activated signaling components. The strongest alterations were 
observed for phosphorylation levels of STAT5 in the nucleus. Here, a significant effect on the 
steady-state value of STAT5 was predicted even for small parameter changes of SOCS3 and 
CIS expression. High expression of SOCS3 led to complete inactivation of the STAT5 
phosphorylation level that recovered at later timepoints due to the negative feedback on 
pathway activation. The comparison of the impact of the two SOCS proteins on the 
modulation of STAT5 phosphorylation levels revealed that the control strength of SOCS3 
exceeded that of CIS. This indicates that the inhibitory effect of SOCS3 on the level of JAK2 
activity is more efficient than the inhibitory action of CIS on the level of EpoR in respect to the 
activation of STAT5. 
Taken together, the simulations revealed that changing SHP-1 concentrations influence the 
initial signal magnitude and duration of JAK2/STAT5 signaling components, whereas the 
levels of the two SOCS proteins fine-tune the extent of the long-term steady-state level.  
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Fig. 27. Simulation of the effect of perturbed SHP-1, CIS and SOCS3 expression levels. 
Simulations were performed by perturbing the parameters controlling SHP-1, SOCS3 or CIS levels. 
The initial value of (a) SHP-1, and the parameters of either (b) SOCS3 or (c) CIS expression were 
incremented logarithmically in 5 steps to 10-fold (1.6, 2.5, 4.0, 6.3, 10) or decreased in 5 steps to 0.1-
fold (0.63, 0.40, 0.25, 0.16, 0.1) and the simulated kinetic behavior of the pathway components were 
plotted. (npSTAT: nuclear phosphorylated STAT5) 
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Application of the CFU-E-derived JAK2/STAT5 pathway model on BaF3-EpoR cells 
In addition to investigating the impact of negative regulators, the mathematical model was 
applied to elucidate the differences in regulatory mechanisms of JAK2/STAT5 signaling 
between BaF3-EpoR and CFU-E cells that were observed in time-course experiments upon 
actinomycin D treatment (Fig. 19). These results showed that in contrast to CFU-E cells, the 
dynamic behavior of the pathway components in BaF3-EpoR cells was not substantially 
affected by actinomycin D, suggesting that induced negative regulators are not involved in 
the attenuation of Epo-signaling in this cell line. This observation may have various reasons 
since numerous differences were observed between BaF3-EpoR cells and CFU-E cells. 
First, the stoichiometries of pathway components in BaF3-EpoR cells differed fundamentally 
from the numbers estimated in primary cells (Table 1). Second, the time-course in BaF3-
EpoR cells showed a rapid degradation of EpoR and JAK2 (Fig. 15). Third, strong Epo 
degradation in the medium was observed after stimulation in BaF3-EpoR cells (provided by 
Verena Becker, DKFZ, Heidelberg). To systematically test whether one of these 
characteristics can explain the observed effects, the mathematical model was employed. 
First, the different stoichiometries of pathway components estimated in BaF3-EpoR cells 
were included in the mathematical model for CFU-E cells. However, the simulations of the 
dynamic behavior were inconclusive with the kinetics observed in BaF3-EpoR cells. To 
address this appropriately would require the estimation of parameters valid for the BaF3-
EpoR cell system because of the different volume of BaF3-EpoR cells compared to CFU-E 
cells. 
The next hypothesis testable with the model of CFU-E cells was the impact of the altered 
input function observed in BaF3-EpoR cells (in collaboration with Verena Becker, DKFZ, 
Heidelberg). Quantitative immunoblotting of Epo revealed that after stimulation of BaF3-
EpoR cells with 5 U/ml Epo the ligand concentration in the medium showed an exponential 
decay due to receptor-mediated endocytosis. In contrast, the effect of Epo degradation in 
CFU-E cells at high doses was only marginal. These findings prompted us to apply the model 
and to simulate the dynamic behavior of JAK2/STAT5 signaling components considering the 
exponential decay and continuous input function that were experimentally observed for 
BaF3-EpoR and CFU-E cells, respectively. Additionally, the behavior of the system in the 
presence of actinomycin D was predicted (Fig. 28). Interestingly, when Epo degradation was 
included as input function, the phosphorylation level of STAT5 in presence or absence of 
actinomycin D was in line with the experimental data in BaF3-EpoR cells. In case of a 
constant Epo stimulus, the dynamic behavior reflected the kinetics observed in CFU-E cells.  
The degradation of EpoR and JAK2 may be an additional process that contributes to 
attenuation of the pathway, potentially rendering transcriptional feedback regulators 
dispensable. However, testing whether these characteristic can explain the observed effects, 
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would require a further extension of the mathematical model and the estimation of new 
parameters for BaF3-EpoR cells. 
 
In summary, the application of the mathematical model established for CFU-E cells proposed 
that rapid degradation of Epo in BaF3-EpoR cells may be a possible explanation for the 
different dynamic behavior of the two cell types upon actinomycin D treatment. However, 
further analysis with an extended mathematical model including all characteristics of BaF3-
EpoR cells will be necessary to understand the distinct mechanisms of JAK2/STAT5 pathway 
attenuation in BaF3-EpoR and CFU-E cells. 
2.6.2 Sensitivity analysis of the JAK2/STAT5 pathway 
Besides studying the effect of parameter changes of negative feedback regulators, a global 
sensitivity analysis can provide a deeper insight into the most important processes and 
proteins that control the output of the pathway. Employing this analysis can lead to a better 
understanding of coordination in the pathway and explain why particular genes can be 
 
Fig. 28. Simulation of the dynamic behaviour of JAK2/STAT5 signaling in control cells or 
treated with actinomycin D dependent on different Epo stimuli. (a) Upper panel: Simulated 
kinetics of phosphorylated JAK2, EpoR and STAT considering Epo degradation for actinomycin D 
treated cells (blue) and untreated control cells (black). Lower panel: Time-course data in BaF3-EpoR 
cells in presence or absence of actinomycin D from Fig. 19 with spline approximations. (b) Upper 
panel: Simulated time course with constant Epo stimulus for actinomycin D treated cells (blue) and 
untreated control cells (black) as observed in CFU-E. Lower panel: Time-course data in CFU-E cells 
in presence or absence of actinomycin D from Fig. 19 with spline approximations. 
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converted to oncogenes but others not (Hornberg et al., 2005b). In our system, 
phosphorylated STAT5 in the nucleus (npSTAT5) was chosen as the target variable 
representing the output of the pathway as it is directly involved in the activation of gene 
transcription. Recently, various studies demonstrated that the signal magnitude and duration 
of transcription factor activity may control the specificity of cellular decisions. Hence, different 
characteristics of the dynamic STAT5 profile were defined and investigated individually: (i) 
peak amplitude, (ii) signal duration (total time until signal drops below 18% of the peak 
amplitude), (iii) integral signal strength (area under curve between 0 and 120 min) and (iv) 
steady-state level (last value at 180 min) (Fig. 29a). 
To identify the steps that are most important for controlling these quantities, control 
coefficients were calculated. Positive control coefficients indicate that values for signal 
duration, peak amplitude, integral signal strength and steady-state level increase with higher 
parameter values, while negative control coefficients indicate that higher parameters lead to 
lower values for these quantities. Higher absolute values of control coefficients represent a 
larger influence of the parameter on the specific characteristic of npSTAT5 dynamics. 
Remarkably, the peak amplitude of npSTAT5 is almost exclusively controlled by three 
parameters: the concentration of STAT5 in the cytoplasm as well as its import and export 
rates (Fig. 29b). This result implied that increasing amounts of STAT5 in the cytoplasm lead 
to a larger number of phosphorylated STAT5 in the nucleus at the peak time, while import 
and export parameters represent the rate-limiting steps. Furthermore, the concentration of 
SHP-1 is important for controlling the peak amplitude, although its influence is lower than that 
of STAT5 concentration. 
In contrast to the peak amplitude, the control of integral signal strength, signal duration and 
steady-state level depended on a larger number of processes and all three characteristics 
showed a similar general control pattern. The concentration of SHP-1, deactivation of SHP-1, 
SOCS3 expression and JAK2 inhibition revealed the largest impact. The control coefficient of 
CIS was smaller compared to that of SOCS3 suggesting that CIS protein levels are less 
important for the control of npSTAT5 dynamics. Additionally, the concentration of JAK2 and 
the parameter JAK2 activation were identified to be critical. In contrast, changes of EpoR 
concentrations were predicted to not affect the npSTAT5 signal of the system. STAT5 
concentration was important for the control of signal duration, but had less impact on the 
integral signal strength and steady-state level. 
In summary, the control pattern of the peak amplitude of npSTAT5 differed significantly from 
that of signal duration, integral signal strength and steady-state level. Whereas the amplitude 
is controlled mainly by three parameters (STAT5 concentration and import as well as export 
rates), the control of the other characteristics yielded a broader distribution over various 
steps of the signaling cascade. 
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Fig. 29. Control coefficients for different characteristics of phosphorylated STAT5 in the 
nucleus (npSTAT5). (a) Definitions of the four quantities peak amplitude, signal duration, integral 
signal strength and steady-state that characterize the transient activation profile of phosphorylated 
STAT5 in the nucleus (npSTAT5). (b) Control coefficients of parameters calculated for the four 
characteristics of npSTAT5. Negative (blue); positive (red) and insignificant (green) values of control 
coefficients are represented by a heatmap. 
 
To provide a visual overview of the sensitivity analysis, parameters that control the integral 
signal strength of npSTAT5 were ranked. Therefore, the control coefficients were classified 
to be significant if the absolute value is not smaller that 20% of the largest control coefficient. 
After applying these classification rules, three reactions and one protein with either the 
largest positive or largest negative values were identified (Fig. 30). SOCS3 expression, JAK2 
deactivation by SHP-1 and SOCS3 inhibition were identified as the parameters with the 
largest negative control coefficient whereas SHP-1 deactivation, JAK2 activation and STAT5 
activation by JAK2 were the reactions with the highest positive values. Furthermore, JAK2 
and SHP-1 were revealed as the proteins with the largest impact. 
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Fig. 30. Reactions and proteins displaying the largest control coefficients for the integral 
signal strength of phosphorylated STAT5 in the nucleus. Processes and proteins were classified 
to be essential for controlling the integral npSTAT5 signal by ranking the calculated control 
coefficients. The three reactions with the highest positive (green) control coefficient and highest 
negative (red) control coefficient were highlighted. Protein concentrations with the highest positive 
value (green) and highest negative value (red) of calculated control coefficients were indicated. 
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2.7 Effects of altered negative feedback loops on cellular decisions 
Previous studies have demonstrated that STAT5 is involved in maintaining survival in 
erythroid progenitor cells. To study whether the integral signal strength of nuclear STAT5 
(npSTAT5) correlated with survival, the effect of SHP-1, SOCS3 and CIS overexpression on 
the apoptosis rate of primary CFU-E cells was studied and compared with the simulated 
integral signal strength of npSTAT5 of the mathematical model. At this point, it is important to 
consider that in contrast to the simulations in Fig. 27, in this experiment, the proteins were 
constantly overexpressed and thus, CIS and SOCS3 overexpression is expected to reduce 
the initial peak amplitude. 
Freshly isolated CFU-E cells were retrovirally transduced with either SHP-1, SOCS3 or CIS 
and stimulated with 0.5 U/ml Epo. The expression levels of these proteins in the CFU-E cells 
were quantified by using the LumiImager software (Roche Diagnostics, Mannheim). Because 
of the high level of the endogenous protein, SHP-1 reached only a level of 3.5 fold 
overexpression. SOCS3 and CIS reached 10-fold and 11-fold overexpression levels, 
respectively (Fig. 31a). After 24 h the number of apoptotic cells was analyzed using the 
TUNEL assay which detects DNA breaks. The results of this assay (Fig. 31b) showed that 
the highest rate of apoptosis was observed in cells overexpressing SOCS3. CFU-E cells 
overexpressing CIS showed a small but significant upregulation of apoptosis whereas for 
cells overexpressing SHP-1 no significant effect was observed.  
To calculate the integral signal strength of STAT5 in the nucleus for all four conditions, the 
dynamic behavior of npSTAT5 was simulated considering the different levels of 
overexpression for CIS, SHP-1 and SOCS3 by using the mathematical model. The 
calculation revealed that in SHP-1 overexpressing cells this quantity was reduced only to a 
small extent. The strongest effect on the simulated integral response was calculated for cells 
overexpressing SOCS3 whereas the value calculated for 10-fold CIS overexpression level 
was intermediate. Hence, in the analysis that related the integral response of npSTAT5 to the 
survival rate a good correlation (R2 = 0.9881) with a hyperbolic function was observed, 
indicating a strong dependency of the calculated amount of phosphorylated STAT5 in the 
nucleus and the survival rate of CFU-E cells. 
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Fig. 31. Correlation of integral signal strength of phosphorylated STAT5 in the nucleus and 
survival of CFU-E cells. (a) CFU-E cells were retrovirally transduced with SHP-1, SOCS3 or CIS 
and sorted for positively transduced cells. Cellular lysates were subjected to immunoprecipitation with 
antibodies against SHP-1, CIS or SOCS3 to determine overexpression levels. Bars represent 
quantifications of vector control (light colour) and overexpression (dark colour) of different subsets. 
(b) CFU-E cells overexpressing SHP-1 CIS or SOCS3 were cultured 24 h in 0.5 U/ml Epo. 
Histograms show the representative result of a TUNEL assay used to detect DNA double-strand 
breaks indicative of apoptotic cells. Cells for positive control were treated with DNaseI for 10 min and 
subjected to the TUNEL assay. The bar plot shows the mean ± S.D. percentage of TUNEL positive 
cells in the different CFU-E subsets obtained in three independent experiments, ***P<0.001, **P<0.05 
(paired t-test, two-sided). (c) The JAK2/STAT5 model was used to simulate the response of 
phosphorylated STAT5 in the nucleus (npSTAT5) for the indicated subsets. Bars represent calculated 
values of the integral signal strength (within 120 min) after stimulation with 0.5 U/ml Epo of 
phosphorylated STAT5 in the nucleus for cells overexpressing SHP-1, CIS or SOCS3. (d) Calculated 
values of integral signal strength of npSTAT5 were correlated to the survival rate of CFU-E cells 
determined by the TUNEL assay. 
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3 Discussion 
In this study, a data-based dynamic pathway model was established to examine the different 
roles of negative feedback regulators attenuating the Epo-induced JAK2/STAT5 pathway 
during erythropoiesis. The tyrosine phosphatase SHP-1 was identified as the major negative 
regulator controlling the early phase kinetics of the signaling pathway, whereas the two 
transcriptionally induced regulators SOCS3 and CIS were elucidated as main modulators of 
the long-term steady state STAT5 phosphorylation level. Furthermore, signal amplification of 
Epo-induced JAK2/STAT5 pathway was revealed as a crucial characteristic enabling signal 
transmission at low concentrations of Epo. 
3.1 Establishing standardized experimental techniques for systems biology 
3.1.1 Quantitative techniques for studying EpoR signaling  
The generation of reproducible, quantitative and time-resolved data suitable for systems 
biology approaches requires advanced techniques for data acquisition and processing as 
well as a standardized in vitro cell system (Schilling et al., 2008). Hence, for the 
implementation of a dynamic pathway model of Epo-induced JAK2/STAT5 signaling in 
primary murine erythroid progenitor cells at the CFU-E stage, standard operating procedures 
for the preparation and cultivation of CFU-E cells were established. These procedures 
included the exclusive use of the inbred mouse strain Balb/c for the isolation of erythroid 
progenitors from fetal livers of 13.5 days-old embryos. Furthermore, primary cells were 
routinely cultivated 12-14 h prior to experiments. Starvation time and Epo concentrations for 
the stimulation of CFU-E cells were optimized to induce maximal signal activation within the 
linear range, avoiding signal saturation. Besides establishing standardized protocols for the 
cultivation of primary erythroid progenitors, experimental methods were optimized to meet 
the quantitative requirements for mathematical modeling approaches. 
The quality of data obtained from immunoblotting experiments were optimized by employing 
advanced strategies for error reduction and automated data processing (Schilling et al., 
2005a). In particular, correlated errors typically originating from immunoblotting due to 
inhomogeneities in the gel or the transfer process were prevented by randomized gel 
loading. Data normalization and computational data processing was further improved by 
applying constant amounts of purified calibrator proteins to the cellular lysates. Since 
densitometric scanning of X-ray films displays a narrow linear detection range, a CCD-
camera based LumiImager system was employed to avoid artificial signal saturation and to 
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yield immunoblotting data in digital format. By applying these strategies, a reliable 
experimental setup for the generation of highly reproducible time-resolved data of 
JAK2/STAT5 pathway activation dynamics was established that are suitable for 
mathematical modeling approaches. 
Beyond the optimization of quantitative immunoblotting techniques, a number of novel 
strategies for the quantification of endogenous protein levels and post-translational 
modifications have recently been developed. Protein microarrays are a promising example 
allowing accurate quantification of low-level phosphoproteins in particular from limited 
biological material, such as primary CFU-E cells (Korf et al., 2008). Therefore, this technique 
is currently being optimized in collaboration with Alexandra Kienast, DKFZ Heidelberg to 
quantify the activation of JAK2/STAT5 pathway components. Alternatively, for the 
investigation of large-scale kinetics of proteomes, advanced mass spectrometry (MS) 
techniques based on isotope-coded protein labels (Schmidt et al., 2005) or stable isotope 
labeling with amino acids in cell culture (SILAC) (Mann, 2006) were developed. However, MS 
techniques still require large amounts of material and will need further optimization before 
they can be used for the generation of densely sampled time-course data appropriate for 
mathematical modeling. 
3.1.2 A powerful tool for targeted perturbation - the Tet-On inducible system 
In systems biology, the validation of mathematical models requires efficient experimental 
tools that allow the targeted perturbation of the investigated signaling network (Swameye et 
al., 2003). Hence, for the fine-tuned overexpression of pathway components, an efficient Tet-
On inducible expression system was established that facilitates the tight control of transgene 
expression in a time- and dose-dependent manner.  
Most of the previous Tet-On vector systems were restricted to the usage in transfectable 
adherent cells (Chenuaud et al., 2004; Nagarajan and Sinha, 2008; Urlinger et al., 2000), 
and only few studies described retro- or lentivirus vector-based systems appropriate for 
hematopoietic cells (Barde et al., 2006). Thus, a novel dual retroviral vector system for the 
particular use in hematopoietic cells was constructed that harbors newly developed Tet-On 
system components. Importantly, the two separate viral vectors ensure that the TRE is not 
juxtaposed with the promoter used to drive transactivator expression, thereby avoiding 
background expression in the non-induced state (Lee et al., 2005). For the optimized 
inducibility of the system, two different TREs, a first generation TRE-L (Baron et al., 2000) 
and the second generation TREtight (TRE-T) (H. Bujard, ZMBH Heidelberg) were compared 
in combination with the novel transactivator rtTA-M2. Due to the shortened CMV minimal 
promotor and the optimized TetO sequences, the TRE-T variant showed significantly lower 
background activity in the uninduced state compared to the TRE-L, thereby confirming 
previous reports (Backman et al., 2004). In contrast, the TRE-L variant reached a remarkably 
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higher induction rate in BaF3 cells. Similar results were obtained in a study that compared 
both TRE variants in a lentiviral vector system in human breast carcinoma cells (Pluta et al., 
2005). Hence, both elements are ultimately useful depending on whether low background 
expression levels or high induced transgene expression levels are desired.  
However, this system is not appropriate for the application in primary CFU-E cells, because 
these cells differentiate into erythroblasts after approximately one day in culture and this time 
frame is too short for the ex vivo delivery of the Tet-inducible system. Instead, the generation 
of transgenic mice expressing the rtTA under the control of an erythroid-lineage specific 
promotor will facilitate the investigation of dose-dependent upregulation of negative 
regulatory proteins in vivo. 
3.2 Signal amplification in the Epo-induced JAK2/STAT5 pathway 
Signal amplification is a well-known phenomenon in signal transduction pathways. However, 
only few studies have adressed this characteristic in mathematical terms (Heinrich et al., 
2002; Legewie et al., 2005; Sourjik and Berg, 2002). By employing a data-based dynamic 
model of the core module of Epo-induced JAK2/STAT5 signaling, a sigmoidal behavior with 
maximal responsiveness of the pathway was observed for low Epo concentrations, while at 
high stimuli STAT5 levels become saturated (Vera, Bachmann et al, 2008). Interestingly, this 
behavior is in line with previous studies that described this characteristic as a typical feature 
of amplifying signal transduction pathways (Chaves, 2004). Heinrich et al. (2002) 
emphasized this issue in the analysis of the MAPK cascade, demonstrating that a weakly 
activated pathway leads to higher amplification, while for strong stimuli only lower levels of 
amplification are reached (Heinrich et al., 2002). To further quantify the ability of the 
JAK2/STAT5 pathway to amplify the Epo-induced signal, the logarithmic amplification factor 
(LA) was defined as the logarithm of the ratio between the total amount of activated STAT5 
in the nucleus and activated EpoR. Consistent with the previous analysis, the LA factor 
demonstrated that the system acts as a strong amplifier between the activated pathway 
components EpoR and STAT5. Interestingly, maximal increase in amplification was observed 
for the levels of low stimuli including the physiological plasma concentrations of Epo at 
steady-state conditions (Jelkmann, 2004). This suggests that the system is designed to 
maximally amplify the signal at biologically relevant Epo concentrations, thereby facilitating 
efficient cellular responses (Vera, Bachmann et al, 2008). 
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3.3 Quantitative dynamic data on Epo-induced JAK2/STAT5 signaling 
3.3.1 Quantitative analysis of JAK2/STAT5 pathway activation dynamics 
Time-resolved quantitative data of pathway activation is an important requirement for 
mathematical modeling. In addition to the dynamic behavior, the knowledge of the 
stoichiometries of pathway components is useful to determine the initial values of species in 
the mathematical model. Therefore, by using serial dilutions of recombinant calibrator 
proteins, the absolute amounts of JAK2/STAT5 signaling components including the negative 
regulators SHP-1, CIS and SOCS3 were determined in primary CFU-E cells and in BaF3-
EpoR cells, which exogeneously express the EpoR. Although BaF3-EpoR cells are a 
frequently used model system to study Epo-dependent signaling (Moucadel and 
Constantinescu, 2005), severe alterations in the stoichiometries between primary CFU-E 
cells and BaF3-EpoR cells were observed. In particular, BaF3-EpoR cells show higher 
amounts of STAT5 compared to primary cells and the SHP-1 level was with approximately 
450.000 molecules per cell in BaF3-EpoR 50-fold higher than in CFU-E cells with 
approximately 8,500 molecules per cell. In a similar approach using serial dilutions of protein 
standards, SHP-1 levels were estimated to be 800,000 molecules per cell in naïve OT-1 T-
cells (Altan-Bonnet and Germain, 2005), indicating that the amounts of SHP-1 differ 
considerably between cell-types. Moreover, the relative expression levels of STAT5 and 
SHP-1 are often dysregulated in leukemic cell lines (Pao et al., 2007b; Wu et al., 2003).  
In addition to the altered stoichiometries, the dynamic behavior of JAK2/STAT5 signaling in 
BaF3-EpoR cells differed in multiple aspects from the kinetic observed in primary cells. In 
contrast to CFU-E cells, that showed constant levels of the proteins JAK2 and EpoR, in BaF3 
cells the two proteins were strongly degraded after long-time stimulation with Epo. Moreover, 
attenuation of JAK2/STAT5 signaling was not dependent on de novo protein synthesis, 
indicating that induced transcriptional regulators such as SOCS3 and CIS play no major role 
in the regulation of JAK2/STAT5 signaling in this cell line. These findings emphasize the 
importance of the use of primary erythroid progenitor cells to gain a deeper insight into the 
regulation of EpoR signaling in vivo during erythropoiesis (Wickrema et al., 2007). 
In primary CFU-E cells, the activation profile of EpoR, JAK2 and STAT5 followed a sharp 
peak that declined to a lower steady state level, typical for adaptive cytokine-induced 
responses (Tsuji-Takayama et al., 2006). CIS and SOCS3 were induced and remained at a 
constant high level similar to the kinetics of their respective mRNA levels. Since mRNA and 
proteins of SOCS family members have been reported to be very short-lived with a half-life of 
less than one hour (Wormald et al., 2006), either the level of phosphorylated STAT5 in the 
nucleus is sufficient to maintain these long-term expression or other factors may be involved 
that increase the mRNA stabilities (Ehlting et al., 2007). The tyrosine phosphatase SHP-1 is 
constitutively expressed and the protein level remained constant over the entire period of 
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observation. Because the catalytic activity of SHP-1 is regulated by an intramolecular 
conformational change (Barford et al., 1998; Jones et al., 2004; Neel et al., 2003; Pei et al., 
1996; Zhang et al., 2003), the dynamics of SHP-1 activation could not be studied directly 
using our experimental setup. Previous studies analyzed the dynamics of SHP-1 activation in 
vitro using p-nitrophenyl phosphate as substrate and synthetic peptides mimetics of the 
EpoR phosphotyrosine residue Y429 to activate the catalytic activity (Pei et al., 1994). 
However, the activation dynamics determined in vitro often differ from the situation in vivo 
due to the specific subcellular environment. As an alternative strategy, mathematical 
modeling can provide useful tools to gain insight into the dynamic function of SHP-1 activity. 
3.3.2 Differential upregulation of SOCS proteins 
Several inducible negative feedback proteins of the SOCS family have been implicated in the 
attenuation of Epo-induced signaling including CIS, SOCS1, SOCS2 and SOCS3 (Sasaki et 
al., 2000; Starr et al., 1997; Yoshimura et al., 1995). However, the detailed contribution of the 
SOCS proteins involved in EpoR signaling during in vivo erythropoiesis remained unclear, 
since most of the previous studies used transformed erythroleukemic cell lines, such as R11 
or J2E whose expression patterns differ considerably from normal erythroid progenitor cells 
(Sarna et al., 2003; Wickrema et al., 2007). For this reason, primary erythroid progenitor cells 
were employed to gain deeper insight into the role of SOCS proteins during normal 
erythropoiesis. 
As evidenced by time-resolved expression profiling of primary erythroid cells at the CFU-E 
stage, only CIS and SOCS3 show rapid and permanent upregulation at the mRNA level upon 
stimulation with Epo. These findings are in line with the presence of STAT5 consensus sites 
in the promoters of CIS (Matsumoto et al., 1997) and SOCS3 (Barclay et al., 2007). In 
contrast, neither SOCS1 nor SOCS2 mRNA expression were detected in CFU-E cells 
suggesting that these SOCS proteins are either primarily expressed in transformed cell lines 
or as hypothesized by Sarna et al. (2003) may be induced in other stages during erythroid 
maturation. The analysis of SOCS expression in the hematopoietic cytokine-dependent cell 
line BaF3-EpoR, show the induction of SOCS1 and SOCS6 additionally to CIS and SOCS3. 
Similarly, Epo-dependent upregulation of CIS and SOCS1, -2, -3 has been reported in the 
cell lines 32D-EpoR and HCD57 (Jegalian and Wu, 2002). Hence, Epo-induced upregulation 
of SOCS genes occurs in a cell type-specific manner, emphasizing the importance of the use 
of primary cells in studies on Epo-dependent signaling during erythropoiesis. 
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3.4 Mathematical model of negative feedback regulation in the JAK2/STAT5 pathway 
3.4.1 Evaluation of the dynamic JAK2/STAT5 model 
Most of the previously published JAK/STAT models have a complex structure comprising a 
large number of variables and parameters (Soebiyanto et al., 2007; Yamada et al., 2003; Zi 
et al., 2005). Since these approaches frequently lack quantitative data for the appropriate 
calibration, the models often contain non-identifiabilities. 
In this work, as an alternative modeling strategy, a reductionistic bottom-up approach was 
employed, which aims at fully identifiable parameters that are essential to obtain models with 
high predictive power (Aldridge et al., 2006; Bruggeman et al., 2002). The number of 
reactions in the mathematical model was reduced by introducing several assumptions and 
simplifications. The JAK2/STAT5 pathway was considered as an independent module, which 
is not influenced by other Epo-induced signaling pathways. Reactions and proteins were 
limited the core module of JAK2/STAT5 signaling, such as the EpoR, JAK2 and STAT5 as 
well as the three negative regulators SHP-1, CIS and SOCS3. Protein complexes and rapid 
reactions that were identified not to be essential for describing the data, as revealed by 
comparison of the respective model-data compliances were neglected. Moreover, alternative 
mechanisms that may be involved in the inactivation of Epo-induced signaling, such as 
receptor internalization (Walrafen et al., 2005) have not been included, since model versions 
considering EpoR endocytosis could not improve the model fits. The systematical 
condensation of the reactions and species in the mathematical model resulted in a total 
number of 13 ordinary differential equations and 17 parameters. This established model 
could simultaneously describe multiple different data sets of Epo-induced JAK2/STAT5 
signaling monitored under five different conditions including total and phosphorylated levels 
of EpoR, JAK2, STAT5 and total levels of CIS and SOCS3. As demonstrated by fit sequence 
analysis a global parameter optimum of the multi-experiment fitting was determined showing 
that all parameters in the model are identifiable. Additionally, confidence intervals of all 
estimated parameters confirmed a high accuracy for model predictions.  
3.4.2 Model-based elucidation of the temporal control of JAK2/STAT5 signaling 
The temporal regulation of Epo-induced signal transduction is crucial for the controlled 
balance of erythrocyte production. Despite the administration of a sustained Epo stimulus, 
JAK2/STAT5 pathway activation is rapidly attenuated to a lower phosphorylation level, 
suggesting an effective inhibition via feedback mechanisms that lead to the long-term 
adaption of the system (Behar et al., 2007).  
By data-based mathematical modeling, the rapid recruitment and fast activation of the 
constitutively expressed phosphatase SHP-1 was identified as the major mechanism 
controlling the early-phase kinetics of pathway activation. At later time points, negative 
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regulation by SHP-1 is accompanied by the two transcriptionally induced regulators SOCS3 
and CIS, which fine-tune the extent of the STAT5 long-term phosphorylation level in primary 
erythroid progenitor cells (Fig. 32). 
 
Fig. 32. Schematic overview of the temporal control of Epo-induced JAK2/STAT5 signaling by 
negative feedback loops in primary CFU-E cells. Schematic representation of the different phases 
(I-IV) of JAK2/STAT5 signal activation showing the EpoR (grey) with the associated tyrosine kinase 
JAK2 (orange), STAT5 (light green) and the tyrosine phosphatase SHP-1 (dark green) (upper level). 
(I) In the basal state, the constitutively expressed phosphatase SHP-1 is present in an inactive state in 
the cytoplasm. (II) Upon Epo binding, the receptor-associated JAK2 is activated and subsequently 
phosphorylates the EpoR on various cytoplasmic tyrosine residues, which recruits the SH2-domain 
containing proteins STAT5 and SHP-1. (III) The tyrosine phosphatase SHP-1 is activated by an 
intramolecular conformational change upon binding to the EpoR and controls the early-phase kinetic 
of pathway activation. (IV) During late-phase signaling, the transcriptionally induced feedback 
regulators CIS and SOCS3 fine-tune the long-term steady state phosphorylation level of STAT5 in 
addition to SHP-1, thereby enabling tight control of STAT5 induced responses. The corresponding 
phases of the activation profile of phosphorylated STAT5 in the nucleus (highlighted in grey) represent 
the basal state, initiation, early-phase STAT5 activation and late-phase steady state kinetic (lower 
level). 
 
These findings are supported by several lines of experimental and theoretical evidence. First, 
only SOCS3 and CIS mRNA levels showed strong and persistent Epo-dependent 
upregulation in primary CFU-E cells, whereas other SOCS proteins such as SOCS1 or 
SOCS2 that have been previously associated with EpoR signaling were not responsive. 
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Second, Epo-induced CFU-E cells treated with actinomycin D showed elevated levels of 
STAT5 long-term phosphorylation indicating the involvement of de novo gene transcription in 
the regulation of late-phase signaling. In contrast, the kinetics of the initial phosphorylation 
maxima of EpoR, JAK2 and STAT5 in actinomycin D-treated cells were not altered compared 
to the control, thus suggesting that the initial response is regulated by post-transcriptional 
events. Third, time-course experiments in CFU-E cells overexpressing SOCS3, CIS, or SHP-
1 demonstrated the effective and specific inhibition of EpoR signaling by these proteins at 
different levels of signal transmission. As an efficient inhibitor of JAK2, SOCS3 has been 
described to block enzymatic activity of the kinase by binding to the catalytic cleft via its 
kinase inhibitory domain (KIR) (Sasaki et al., 1999). Additionally, SOCS3 is recruited to the 
tyrosine-phosphorylated EpoR residue Y401 and competes with STAT5 for this receptor 
binding site (Hortner et al., 2002; Sasaki et al., 2000). In line with these reports, 
overexpression of SOCS3 in this study strongly inhibited the phosphorylation of JAK2, EpoR, 
and STAT5, supporting its proposed function to inhibit the pathway at multiple levels. 
Remarkably, the mechanism of STAT5 binding site competition on the tyrosine-
phosphorylated EpoR residue Y401 has also been reported for CIS (Ketteler et al., 2003; 
Verdier et al., 1998a). However, in contrast to SOCS3, CIS does not contain a KIR domain 
for inhibiting JAK activity (Endo et al., 1997). Accordingly, diminished phosphorylation levels 
of STAT5 in CFU-E cells overexpressing CIS were observed, whereas JAK2 phosphorylation 
was not affected. As a prominent phosphatase in EpoR signaling, SHP-1 has been shown to 
be recruited to the phosphorylated tyrosine residues Y429 and Y431 of the EpoR and to 
subsequently inhibit JAK2 activation (Klingmüller et al., 1995; Yi et al., 1995). Consistent with 
these reports, our results for SHP-1 overexpression showed a modest but significant 
reduction of phosphorylation levels of JAK2 and EpoR as well as STAT5. Since STAT5 has 
been shown to be no direct substrate of SHP-1 in CFU-E cells by using substrate trapping 
mutants of SHP-1, the effect on STAT5 phosphorylation may be indirectly transmitted from 
JAK2 to the level of STAT5. 
Finally, the central model hypothesis that SOCS3, CIS and SHP-1 differentially regulate Epo-
induced JAK2/STAT5 was supported by the multi-experiment fitting results of diverse data-
sets, which demonstrated a good compliance of the model trajectories and experimental 
data. Notably, initially tested model versions, lacking one of the three negative feedback 
proteins only poorly reflected the experimental data and were therefore rejected. Using the 
correctly calibrated mathematical model, simulations of the dynamic behavior of pathway 
components with varying parameters of SHP-1 expression levels demonstrated that duration 
and strength of the initial phosphorylation peak is controlled by the levels of phosphatase 
activity. Moreover, altered SOCS3 or CIS expression levels influenced the long-term 
phosphorylation level of STAT5. 
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This temporal regulation pattern, including short-term deactivation by constitutively 
expressed phosphatases and late-phase modulation by slow transcriptional feedbacks may 
evolve as a general paradigm for tightly controlled cytokine-induced signaling pathways 
(Legewie et al., 2008). The presence of multiple overlapping feedback regulation 
mechanisms, each with distinct temporal characteristics, thereby ensures the effective 
control of the signaling outcome to appropriately fine-tune cellular responses (Hao et al., 
2007). 
3.4.3 Attenuation of EpoR signaling is cell type-specific 
Hematopoietic cell lines are a frequently used tool for studying JAK/STAT signaling pathways 
by mathematical modeling as they can be easily expanded in culture and are readily 
susceptible to retroviral expression systems. However, these cells harbor severe alterations 
in the signaling behavior compared to primary cells as revealed in this as well as in previous 
studies (Drexler et al., 2004; Wickrema et al., 2007). 
By systematically comparing JAK2/STAT5 signaling in the cell line BaF3-EpoR and primary 
CFU-E cells, a number of striking differences were observed. First, the stoichiometries of 
signaling components determined for BaF3-EpoR and CFU-E cells differed considerably. 
Second, attenuation of JAK2/STAT5 signaling in BaF3-EpoR cells is not dependent on de 
novo protein synthesis despite the induction of four SOCS genes in these cells. This 
behavior could not be explained by the different stoichiometries determined for BaF3-EpoR 
cells using the mathematical model established for CFU-E cells. Presumably, alternative 
mechanisms are involved in the downregulation of JAK2/STAT5 signaling in BaF3-EpoR 
cells that may render SOCS proteins dispensable. These mechanisms may include receptor 
endocytosis, the degradation of the ligand Epo or the degradation of the tyrosine kinase 
JAK2. 
Recently, receptor endocytosis followed by lysosomal and proteasomal degradation has 
been proposed to mediate the downregulation of activated EpoR complexes in the human 
myeloid cell line UT-7 (Walrafen et al., 2005). However, our studies in BaF3-EpoR cells 
revealed that the internalized receptor pool recovers at the cell surface while EpoR activation 
declines (Becker et al., submitted). This observation argues against the assumption that 
long-term attenuation of EpoR signaling is mediated by internalization and degradation of the 
EpoR. Instead, rapid clearance of the ligand Epo facilitated by constitutive receptor turnover 
was identified as an efficient mechanism to downregulate Epo signaling in BaF3-EpoR cells. 
Based on this observation, the behavior of JAK2/STAT5 signaling was simulated considering 
the experimentally determined exponential decay function of Epo using our mathematical 
model (kindly provided by V. Becker). Remarkably, the simulated kinetics of JAK2/STAT5 
signaling showed rapid deactivation of EpoR signaling independent from the presence of 
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SOCS proteins. Hence, rapid degradation of the ligand Epo in BaF3-EpoR cells may be the 
dominant mechanism for attenuating EpoR signaling in this cell line. 
Besides ligand degradation, recent studies in mouse embryonic fibroblasts proposed that 
upon Epo stimulation, JAK2 is autophosphorylated on a negatively regulating tyrosine within 
the receptor-binding FERM domain. This leads to dissociation from the EpoR and 
subsequent kinase degradation (Funakoshi-Tago et al., 2006). In line with this report, strong 
degradation of JAK2 was observed upon Epo stimulation in BaF3-EpoR cells. Notably, JAK2 
levels in primary CFU-E cells remained stable over the entire period of observation. 
Considering the lower endogenous levels of JAK2 in BaF3-EpoR cells compared to CFU-E 
cells, the availability of JAK2 for receptor phosphorylation may be a limiting factor for long-
term EpoR activity in BaF3-EpoR cells. To test this hypothesis, further analysis including 
JAK2 degradation in the mathematical model is desirable. 
3.5 Physiological roles of SHP-1, SOCS3 and CIS 
3.5.1 Potential redundant roles of SOCS3 and CIS during erythropoiesis 
Based on our model analysis, the two proteins SOCS3 and CIS were identified as important 
feedback regulators modulating the STAT5 phosphorylation level in primary CFU-E cells. 
However, their specific roles in fetal liver erythropoiesis in vivo remain unclear. 
STAT5 has been suggested in numerous studies to mediate protection from apoptosis by 
directly inducing the expression of the antiapoptotic protein Bcl-xL in erythroid and 
hematopoietic cells (Ariyoshi et al., 2000; Dumon et al., 1999; Garcon et al., 2006; 
Socolovsky et al., 1999). Importantly, decreased expression of Bcl-xL and increased 
apoptosis in adult and neonatal STAT5ab-/- knockout early erythroblasts correlates with the 
degree of anemia (Dolznig et al., 2006; Socolovsky et al., 2001). In this study, 
overexpression of SOCS3 as well as CIS resulted in a significant increase of apoptotic cells. 
The extent of the survival rate strongly correlated with the decreased STAT5 phosphorylation 
strength calculated for SOCS3 and CIS overexpression. This suggests that the amount of 
SOCS3 and CIS in erythroid progenitor cells sets a threshold to STAT5 survival signals to 
tightly control the production of erythroid progenitor cells. The fact that two SOCS members 
with redundant roles are involved in EpoR-signaling underscores the requirement to 
effectively and appropriately fine-tune STAT5-mediated responses. Notably, several other 
cytokine-induced signaling cascades have been reported to be controlled by more than one 
member of the SOCS family including JAK/STAT signaling through the GHR (Denson et al., 
2003), IL-4Rα (Haque et al., 2000) and prolactin receptor (Pezet et al., 1999). Hence, the 
redundancy of SOCS proteins may be a common mechanism to ensure the tight control of 
cytokine-induced responses. 
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Interestingly, SOCS3 inhibits STAT5 phosphorylation more effectively than CIS as revealed 
by our sensitivity analysis and overexpression experiments in CFU-E cells. Presumably, the 
inhibition of the upstream kinase JAK2 by SOCS3 seems to be more effective than inhibiting 
STAT5 directly by binding site-competition at the EpoR cytoplasmic domain. Consistent with 
the role of SOCS3 as an effective inhibitor for EpoR signaling, SOCS3 transgenic mice have 
been previously reported to be embryonically lethal due to the suppression of fetal liver 
erythropoiesis (Marine et al., 1999). In the same study, the deletion of SOCS3 resulted in 
erythrocytosis and accumulation of nucleated cells in the fetal liver, indicating that SOCS3 is 
a critical regulator of normal erythropoiesis. In contrast to SOCS3, which may affect also 
other pathways elicited by the EpoR and JAK2 including the MAPK and PI3K cascade, CIS is 
a specific regulator of STAT5. In erythroid progenitor cells, forced expression of CIS has 
been previously shown to inhibit STAT5-mediated survival signals (Ketteler et al., 2003) and 
another study showed diminished expression levels of STAT5 target genes in hematopoietic 
cells overexpressing CIS (Matsumoto et al., 1997). The specific inhibition of STAT5 
responses is in line with studies of CIS transgenic mice, which exhibit a remarkably similar 
phenotype to that observed in STAT5ab knockout mice (Matsumoto et al., 1999). Although 
mice deficient for CIS have not been studied in detail, it was reported that these mice show 
no significant abnormalities (Marine et al., 1999). This may be in part explained by the 
functional redundancy of SOCS3 and CIS and further studies will be necessary to dissect the 
physiological functions of these two SOCS proteins during in vivo erythropoiesis. 
3.5.2 The role of SHP-1 in erythropoiesis 
The modeling results propose a major role for SHP-1 in controlling the initial signal 
magnitude of EpoR signaling, however, their precise role in fetal liver erythropoiesis needs to 
be further addressed. 
Two mouse strains with mutations in the SHP-1 gene have been extensively used to 
characterize the physiological function of SHP-1 in hematopoiesis. The murine motheaten 
mutation (me) results in a complete absence of SHP-1 activity, whereas the motheaten 
viable mutation (mev) retains 10% to 20% of SHP-1 activity. These mice develop a multi-
lineage hematopoietic disease that includes polycythemia, accumulation of macrophages 
and neutrophils in the lung and in the skin, causing the characteristic motheaten appearance 
of the coat (Shultz et al., 1997). The phenotypes of me/me and mev/mev differ only in 
severity, with me/me mice dying earlier (at 2-3 weeks) than mev/mev (at 9-12 weeks). 
Interestingly, CFU-E progenitors of mev/mev mice are stimulated by lower than the normal 
concentration of Epo (Van Zant and Shultz, 1989), supporting the model prediction that SHP-
1 is the major negative regulator to control phosphorylation levels of EpoR and JAK2. 
Moreover, cells expressing EpoR mutants incapable of SHP-1 binding show prolonged 
phosphorylation in response to Epo (Klingmüller et al., 1995) which is in line with the 
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assumption that SHP-1 has to be activated by binding to the EpoR before it 
dephosphorylates its target proteins. To elucidate the role of SHP-1 in more detail, 
conditional knockout mice defective for SHP-1 specifically in the erythroid lineage are 
desirable to clarify the physiological relevance of this phosphatase during erythropoiesis. 
3.6 Targeting JAK/STAT signaling in leukemia 
Constitutive STAT activation has been associated with a number of hematological 
malignancies including chronic and acute leukemias and myeloproliferative disorders. To 
shed light on the critical components and reactions that control the output of a signaling 
pathway, sensitivity analysis of accurate mathematical models has been proposed to be a 
promising tool (Hornberg et al., 2005a). 
In this study, sensitivity analysis was applied to calculate to what extent each process in the 
JAK2/STAT5 pathway controls the activation profile of phosphorylated STAT5 in the nucleus. 
The analysis revealed that the concentrations of JAK2 and SHP-1 as well as the parameter 
SOCS3 expression are most critical for controlling the integral signal strength of STAT5. 
Thereby, the concentration of JAK2 showed the highest positive control coefficient, implying 
that the system is in particular sensitive to higher expression levels of JAK2. In contrast, 
SHP-1 levels and the parameter controlling SOCS3 expression possess the two largest 
negative values, indicating that the reduction of these proteins severely alter the signaling 
outcome. Interestingly, these findings are in accordance with the experimentally verified 
observation that JAK2 is an oncogene (Baker et al., 2007) whereas SHP-1 was proposed as 
a candidate tumour suppressor gene (Wu et al., 2003). In particular, amplification of the JAK 
locus and constitutively active JAK2 mutants have been frequently identified in the majority of 
patients suffering from polycythemia (Baxter et al., 2005; James et al., 2005; Kralovics et al., 
2005; Levine et al., 2005). Furthermore, inactivation of SHP-1 by promoter hypermethylation 
was described in various kinds of leukemia, lymphomas and multiple myeloma (Chim et al., 
2004; Johan et al., 2005; Khoury et al., 2004; Oka et al., 2002; Zhang et al., 2000). The role 
of SOCS3 in transformed cells has not yet been studied in detail, but increasing evidence 
suggests that the expression of SOCS proteins is altered in a number of hematopoietic 
malignancies. Deletion of SOCS3 has been shown to result in polycythemia, a premalignant 
form of erythroid leukemia, demonstrating that a loss-of-function mutation may contribute to 
cellular transformation (Marine et al., 1999). Furthermore, SOCS-1, the most similar SOCS 
family member to SOCS3, has been recently identified as tumor suppressor that can 
counteract cell proliferation induced by the oncogenic TEL-JAK2 fusion protein (Rottapel et 
al., 2002). In support of this idea, two recent studies reported that the SOCS1 locus is 
epigenetically silenced by hypermethylation in hepatocellular carcinomas (Nagai et al., 2001; 
Yoshikawa et al., 2001). 
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In summary, the sensitivity analysis revealed that the control of the system output is 
distributed over several proteins and reactions. This indicates that a combination of events is 
involved in the pathogenesis of hematopoietic disorders. In fact, there are numerous recent 
studies showing that JAK activating mutations are complemented by SOCS and SHP-1 gene 
silencing in several malignant tumors (Chim et al., 2004; Johan et al., 2005; Jost et al., 
2007). Thus, control analysis of accurate mathematical models is not only a tool to discover 
an new category of drug targets (Cascante et al., 2002), but also provides insights into the 
dynamic properties of signaling cascades. 
3.7 Conclusions and outlook 
In conclusion, a dynamic pathway model of Epo-induced JAK2/STAT5 signaling including 
negative feedback proteins in primary CFU-E cells was established based on quantitative, 
time-resolved experimental data. The mathematical model could simultaneously describe 
data derived from multiple experiments and comprised identifiable parameters with small 
confidence intervals important for accurate simulations. By extensive model analysis, the 
rapid recruitment of the phosphatase SHP-1 was identified to control the early-phase kinetics 
of pathway activation, while the two transcriptionally induced regulators SOCS3 and CIS 
were revealed as modulators that fine-tune the extent of the STAT5 long-term 
phosphorylation level. These results demonstrate that complementary negative feedback 
mechanisms have evolved that tightly control STAT5 survival signals in erythroid progenitor 
cells. Furthermore, signal amplification of Epo-induced JAK2/STAT5 pathway was revealed 
as a crucial characteristic enabling signal transmission at low concentrations of Epo. 
Moreover, systematic comparison of stoichiometries and activation dynamics of Epo-induced 
JAK2/STAT5 signaling in CFU-E and BaF3-EpoR cells revealed fundamental differences 
between both cell types, emphasizing the importance of the use of primary cells in the 
investigation of EpoR signaling 
Based on the established model, the striking differences in Epo-induced signaling observed 
between primary CFU-E cells and the BaF3-EpoR cell line should be further elucidated. 
Therefore, to achieve this, the mathematical model needs to be extended by introducing 
several characteristics determined for BaF3-EpoR cells. After estimation of new parameters 
valid for BaF3-EpoR cells, sensitivity analysis can be applied to identify the crucial 
mechanisms that control JAK2/STAT5 pathway activation in the cell line and to compare 
these mechanisms with primary cells. This issue can be further addressed using an 
experimental design approach (Maiwald et al., 2007) that systematically selects the most 
informative experiments by means of computational simulations. 
In CFU-E cells, SOCS3 and CIS have been identified as negative regulators of the long-term 
phosphorylation level of STAT5 using model simulations. To directly validate these findings 
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experimentally and to gain more insight into the specific roles of the two proteins controlling 
survival signals in erythroid progenitor cells, siRNA-mediated downregulation of SOCS3 and 
CIS is currently being established. However, conventional retro- and lentiviral vector systems 
for the delivery of small hairpin RNA (shRNA) only resulted in insufficient knockdown in CFU-
E cells. Therefore, new vector systems need to be developed with optimized applicability in 
hematopoietic progenitor cells. As alternative strategy, conditional knockout mice defective 
for CIS or SOCS3 specifically in the erythroid lineage will be desirable to clarify the 
physiological relevance of these negative feedback regulators during erythropoiesis. 
Furthermore, global sensitivity analysis uncovered the parameter SOCS3 inhibition amongst 
others as critical to control the outcome of the JAK2/STAT5 pathway. This strong inhibitory 
effect of SOCS3 on JAK2 activation could be exploited to design peptide mimetics of the 
SOCS3 kinase inhibitory region (KIR) and examine whether these molecules can block 
aberrant activation of JAK2 in transformed leukemic cells. 
 
The detailed understanding of the molecular processes and regulatory mechanisms of Epo-
induced signaling during normal erythropoiesis in primary erythroid cells can be applied to 
gain insights into the alterations driving erythroleukemia and related malignant hematopoietic 
diseases. Considering the complex coordination and control distribution of JAK/STAT 
signaling, our mathematical model may assist in the identification of new drug targets and 
enable to theoretically estimate the effects of corresponding drugs prior to clinical application. 
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4 Materials and Methods 
4.1 Molecular biology techniques 
4.1.1 Generation of competent E. coli cells 
For high-efficiency transformation of plasmid DNA, the E. coli strain Subcloning Efficiency™ 
DH5α™ Cells (Invitrogen) was used to prepare chemically competent bacteria. DH5α cells 
were cultured in 500 ml LB medium up to an optical density of 0.6-0.8 as measured at 600 
nm. After incubation on ice for 10 min, cells were sedimented with 4,100 g for 5 min at 4°C 
and resuspended in 150 ml TFBI (100 mM RbCl, 50 mM MnCl2, 10 mM CaCl2, 30 mM 
potassium acetate, 15% glycerol, pH 5.3). Following 20 min of incubation on ice, cells were 
centrifuged for 5 min at 1,400 g and 4°C, resuspended in 10-15 ml TFBII (10 mM RbCl, 75 
mM CaCl2, 10 mM MOPS pH 7.0, 15% glycerol). Aliquots were stored at -80°C. 
4.1.2 Purification of plasmid DNA 
Plasmid DNA was amplified using E. coli cultures either on small analytic or large preparative 
scale. To isolate plasmid DNA on small scale, E. coli cells were cultured o/n at 37°C in 2 ml 
LB medium supplemented with 100 µg/ml ampicillin. The QIAprep® Spin Miniprep Kit 
(Qiagen) was used according to the manufacturer’s instructions. To prepare plasmid DNA in 
large scale, a single colony or 50 µl of an E. coli culture were cultured in 200 ml LB medium 
supplemented with 100 µg/ml ampicillin for 16-18 h at 37°C. For purification, the JETSTAR 
2.0 Maxi Kit (Genomed) was used according to the manufacturer’s instructions. 
4.1.3 Quantitative analysis of nucleic acids 
The concentration of DNA solutions was determined by measuring the absorbance at 260nm 
(Ultrospec 3100 pro, GE Healthcare). 
4.1.4 Automated DNA sequencing 
All DNA sequences were verified by sequencing service of MWG Biotech AG, Martinsried, 
Germany. 1 µg of plasmid preparations were provided for this purpose. 
4.1.5 Amplification of DNA fragments 
For specific amplification of DNA by PCR a PTC-200 Thermo Cycler (MJ Research) was 
used. The number and duration of cycles as well as the annealing temperatures were 
optimized corresponding to the expected product length and primers. PCR amplification was 
performed in a 50 µl reaction volume containing 50 ng template DNA, 100 µM of each dNTP, 
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1 µM of forward and reverse primer, 10% of DMSO, 2.5 units Cloned Pfu DNA Polymerase 
(Stratagene) and buffer according to the manufacturer’s manual. 
4.1.6 Annealing of double-stranded DNA adapters 
To produce double-stranded DNA adapters that contain specific restriction sites 100 pmol of 
complementary sense and anti-sense primers were heated in annealing buffer (10 mM Tris 
pH 8.0, 300 mM NaCl) for 5 min to 95°C. Subsequently, the mixture was cooled to RT during 
30 min and subsequently used for ligation with the corresponding plasmid. 
4.1.7 Molecular cloning of DNA fragments 
To generate specific DNA sequences, restriction of DNA by type II endonucleases was 
performed in a 20 µl reaction volume containing 0.5-1 µg plasmid DNA, 5 U of the restriction 
enzyme, 2 µl of 10x buffer according to the manufacturer’s protocol (New England Biolabs). 
The resulting DNA fragments were separated on a 1 % agarose gel (Invitrogen) 
supplemented with 100 ng/ml ethidiumbromide and excised from the gel using a scalpel. 
After elution and purification of the DNA fragments with the Qiaex®II Gel Extraction Kit 
(Qiagen), vector and an 2-3 fold excess of insert DNA were ligated for 30 min at RT using 1 
µl of Quick T4 DNA Ligase (New England Biolabs) and subsequently transformed into 
competent E. coli DH5α cells. For transformation, competent DH5α dam+ cells were thawed 
on ice and 50 µl of cells were mixed with 0.5 µg of plasmid DNA or 5 µl of ligation reaction. 
After incubation for 20 min on ice, cells were subjected to a heat shock for 5 min at 37°C 
followed by incubation for 10 min on ice. Subsequently, cells were diluted in 1 ml LB medium 
and incubated at 37°C for 30 min. Cells were plated in a total volume of 100 µl on TB agar 
plates (Fluka). The plates were incubated at 37°C o/n and single colonies were picked for 
further cultivation in LB medium supplemented with 100 µg/ml ampicillin. 
4.1.8 Construction of plasmids 
For generation of retroviral expression vectors to establish the tetracycline-inducible 
expression system in hematopoietic cells pMOWS-puro (Ketteler et al., 2002) and pMOWSIN 
were used. pMOWSIN is a self-inactivating (SIN) retroviral vector that lacks the promoter and 
enhancer region of the U3 sequence in the 3’proviral longterminal repeats (LTRs). To yield 
pMOWS-rtTA-M2, cDNA of rtTA-M2 was amplified with primer sequences 5’-
cgggatccatgtctagactggacaagagc-3’ and 5’-cggaattcttagttagttatccggggagc-3’ using pUHrT-62-
1 as template (kindly provided by H. Bujard, ZMBH, University of Heidelberg). The PCR 
fragment was digested with BamHI/EcoRI and ligated into pMOWS. For generation of 
pMOWSIN-TRE-L, the TRE fragment in S2s-lMCg (kindly provided by R. Löw and H. Bujard, 
ZMBH, University of Heidelberg) was digested with XhoI, treated with T4 polymerase and 
subsequently digested with HindIII. The fragment was ligated into pMOWSIN that was 
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digested with PmlI/EcoRI. The TRE-L consists of the original heptamerized Tet-operator 
sequence Ptet-1 with the CMV minimal promoter from position -53 to +75. The pMOWSIN-
TRE-T vector was generated by ligating TRE in pTRE-tight (BD Bioscience Clontech) after 
digestion with HindIII, T4-polymerase treatment and EcoRI digestion in pMOWSIN treated 
with PmlI/EcoRI. The TRE-T sequence contains a modified Tet-operator sequence and a 
shortened CMV minimal promoter. GFP cDNA was cloned into pMOWSIN-TRE-T and 
pMOWSIN-TRE-L vectors using BamHI/EcoRI digestion. cDNA of SHP-1 was ligated into 
pMOWSIN-TRE-L after NdeI/PmlI digestion. 
pMOWS-HA-EpoR (Becker et al., 2008) with a puromycin resistance cassette was used for 
retroviral infection of BaF3 cells to generate stable BaF3-EpoR cell lines. 
pMOWSnr is a derivative of pMOWS where the puromycin resistance gene was replaced by 
the LNGFR cDNA (Miltenyi Biotech), so that transduced cells can be selected by magnetic 
beads. cDNA of SOCS3 and CIS were cloned into pMOWSnr to yield pMOWSnr-SOCS3 and 
pMOWSnr-CIS. Therefore, CIS cDNA and the pMOWSnr were digested with EcoRI/NdeI. 
SOCS3 was digested using BamHI/NdeI and ligated into the pMOWSnr also treated with 
BamHI/NdeI. pMOWSnr-SHP-1 was kindly provided by M. Schilling, DKFZ Heidelberg. 
To generate pSBP-CIS, CIS cDNA was amplified using the primer sequences 5’-
gaagatctatggtcctctgcgtacagggat-3’ and 5’-cggaattctagagttggaaggggtac-3’. The PCR fragment 
was digested with BglII/EcoRI and cloned into pGEX-SBP treated with BglII and EcoRI. 
All sequences were verified by sequencing analysis.  
4.2 Mammalian cell lines, primary cells and cell culture techniques 
If not stated otherwise, mammalian cell culture media and supplements were obtained from 
Gibco. 
4.2.1 Cultivation of mammalian cell lines 
The packaging cell line Phoenix eco was cultured in DMEM medium supplemented with 10% 
FCS and 1% antibiotics (10,000 U/ml penicillin and 10,000 µg/ml streptomycin sulfate). For 
selection of Phoenix eco cells stably expressing Gag-Pol-Env, cells were treated with 2 µg/ml 
Diphtheria toxin (Calbiochem) and 200 µg/ml Hygromycin B (Roche Diagnostics, Mannheim). 
Phoenix eco cells were subcultured by treatment with 0.5 mg/ml Trypsin and 0.2 mg/ml 
EDTA and never cultured longer than 2 weeks prior to transfection. 
The IL-3 dependent murine pro B cell line BaF3 (Palacios and Steinmetz, 1985) was cultured 
in RPMI 1640 medium including 10% WEHI as a source of IL-3 and supplemented with 10% 
FCS and 1% antibiotics. Cells were subcultured after reaching a density of 5-8 x 105 cells/ml. 
For long-term storage, BaF3 or Phoenix eco cells were frozen in liquid nitrogen in 90% 
serum and 10% DMSO at a density of 2.5x106. 
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4.2.2 Preparation of murine fetal liver cells  
At E13.5 Balb/c mouse embryos were isolated from the uterus of sacrificed females. Fetal 
livers of embryos were dissected and resuspended in 500µl ice-cold phosphate-buffered 
saline (PBS) supplemented with 0.3% bovine serum albumin (BSA). After passing through a 
40 μm cell strainer (BD Biosciences), cells were treated with 10 ml Red Blood Cell Lysing 
Buffer (Sigma-Aldrich) to remove erythrocytes. For negative depletion, fetal liver cells of 40 
livers were incubated with 10 µl rat antibodies against the following surface markers: GR1, 
CD41, CD11b, CD14, CD45, CD45R/B220, CD4, CD8 (all purchased from BD Pharmingen), 
Ter119 (gift from Albrecht Müller, Julius-Maximilians-University, Würzburg, Germany) and 
with the rat monoclonal antibody YBM/42 (gift from Suzanne M. Watt, University of Oxford, 
Oxford, UK) for 30 min at 4°C. Cells were washed 3 times in PBS/ 0.3%BSA and were 
incubated for 30 min at 4°C with anti-rat antibody-coupled magnetic beads and negative 
sorted with MACS columns according to the manufacturer's instructions (Miltenyi Biotech). 
Sorted CFU-E were cultivated for 13 h in Iscove's Modified Dulbecco's Medium (IMDM) 
(Invitrogen), 30% fetal calf serum (FCS), and 50 µM β-mercaptoethanol supplemented with 
0.5 U/ml Epo (Cilag-Jansen).  
4.2.3 Preparation of WEHI-conditioned medium 
To prepare IL-3 containing medium, WEHI-3B cells (Ralph and Nakoinz, 1977a; Ralph and 
Nakoinz, 1977b; Warner et al., 1969) were cultured in RPMI 1640 supplemented with 10% 
FCS and antibiotics until confluency. After expansion of the cells in a total volume of 50 ml, 
WEHI-conditioned medium was harvested every 5 days by centrifugation and subsequent 
filtration through a 0.2 µm filter in order to remove cell debris. The remaining adherent cells 
as well as the sedimented cells were further supplied with 50 ml of fresh medium and 
adherent cells were subcultured after 4-6 weeks. 
4.2.4 Transient transfection of Phoenix eco cells 
To produce virus supernatant for subsequent transductions, Phoenix eco packaging cells 
were transfected by the calcium-phosphate method. Transfections were performed either in 
small scale (6-well plates) or large scale (25 cm2 dishes). 
For small scale reactions, cells were seeded at a density of 8x105 cells in 6-well plates 16-18 
h prior to transfection. A mix of 10 µg plasmid DNA and 12.5 µl CaCl2 (2.5 M) was added to 
125 µl of 2x HBS (280 mM NaCl, 50 mM HEPES, 1.5 mM Na2HPO4, pH 7.05) to form the 
precipitate. For large scale reactions cells were seeded at a density of 12x106 in 25 cm2 
dishes and a mix of 150 µg plasmid DNA and 187.5 µl CaCl2 (2.5 M) was added to 1875 µl 2x 
HBS. The suspension was dropwise transferred to the cells. For efficient uptake of DNA, 
cells were incubated for 6-8 h in DMEM medium supplemented with 25 µM chloroquine. 
Subsequently, the medium was replaced by IMDM supplemented with 30% FCS, 1% 
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antibiotics and 50 µM β-mercaptoethanol. The retrovirus-containing supernatant was 
harvested after 16-18 h of incubation and filtered through a 0.45 µm filter (Millipore). 
Supernatants were either directly used for transduction or stored at -80°C for up to 3 months. 
Transfection efficiency was determined by measuring GFP expression in the FL-1 channel of 
a FACSCalibur (Becton Dickinson), in general yielding a GFP-positive population of 70-90%. 
4.2.5 Retroviral transduction 
To stably transduce BaF3 cells, 250 µl retroviral supernatant were supplemented with 8 
µg/ml polybrene, mixed with 1x105 BaF3 cells and centrifuged for 2 h at 340 g and 37°C in 
round bottom 2-ml microcentrifuge tubes. After centrifugation, cells were cultured for 48 h in 
standard medium, subsequently selected and further cultured with 1.5 µg/ml puromycin. 
Transduction efficiency was determined by measuring GFP expression in the FL-1 channel 
of a FACSCalibur (Becton Dickinson), in general yielding a GFP-positive population of 35-
45%.  
To transduce primary erythroid progenitor cells (CFU-E), 4.5 ml retroviral supernatants 
supplemented with 8 µg/ml polybrene were mixed with 3x106 CFU-E cells in a 6-well plate 
and centrifuged for 3 h at 340 g and 37°C. Following spin-infection cells were cultivated for 
12-14 h in IMDM (Invitrogen), 30% FCS, 1 % antibiotics and 50 µM β-mercaptoethanol 
supplemented with 0.5 U/ml Epo (Cilag-Jansen).  
Successfully transduced cells were isolated using the MACSelect LNGFR selection kit 
(Miltenyi Biotech) according to the manufacturer's instructions. Briefly, 1x107 washed cells 
were resuspended in 320 µl PBS/ 0.3% BSA and incubated with 80 µl MACS beads on ice 
for 15 min to magnetically label positively transduced cells. LS columns were placed in the 
magnetic field of a MACS Seperator and rinsed with 3 ml PBS/ 0.3% BSA. Cells were 
applied onto the column in 8 ml PBS/ 0.3% BSA and the flow through was collected as 
negative unlabeled cell fraction. The column was washed four times with 3 ml PBS/ 0.3% 
BSA. To elute the positive fraction, the column was removed from the magnetic field and 
transduced cells were flushed out with 4 ml PBS/ 0.3% BSA by firmly applying the plunger. 
4.2.6 Flow cytometry 
For the analysis of the induction efficiency of the Tet-system, GFP expression was 
determined by flow cytometry using the FL-1 channel of a FACSCalibur (Becton Dickinson). 
Therefore, cells were incubated with different doxycyline concentrations for 24 h and washed 
three times with PBS/0.3 % BSA before the flow cytometry analysis. 
4.2.7 TUNEL assay  
For detection and quantification of apoptosis at single cell level, the In Situ Cell Death 
Detection Kit (Roche Diagnostics, Mannheim) was used. The TUNEL (Terminal 
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deoxynucleotidyl Transferase-mediated dUTP nick end labeling) assay relies on the 
detection of single- and double-stranded DNA breaks that occur during the early stages of 
apoptosis. Apoptotic cells are identified by using TdT to transfer fluorescein-dUTP to these 
strand breaks of cleaved DNA. Briefly, 2x106 CFU-E cells were fixed in freshly prepared 2% 
paraformaldehyde and permeabilised with 0.1% Triton X-100, 0.1% sodium citrate for 2 min. 
The positive control was treated with digestion buffer (DNaseI recombinant, DNaseI buffer, 
Roche Diagnostics, Mannheim) for 10 min. After washing with PBS/ 0.3% BSA, cells were 
resuspended in TUNEL reaction mixture (TdT, fluorescein-dUTP, reaction buffer) to label 
free 3’-OH groups of single- and double-stranded DNA. Fluorescein-dUTP incorporated in 
nucleotide polymers is detected and quantified by flow cytometry using the FL-2 channel of a 
FACSCalibur (Becton Dickinson). For statistical evaluation a two-sided, unpaired Student’s t-
test was performed with P<0.05 considered significant. 
4.3 Biochemical and immunological protein analysis 
4.3.1 Time-course experiments in BaF3-EpoR and CFU-E cells 
BaF3-EpoR cells were washed three times with RPMI 1640 and starved for 3-5 h at 37°C in 
RPMI 1640 supplemented with 1 mg/ml BSA. CFU-E cells were washed three times and 
starved in Panserin 401 (PAN Biotech) supplemented with 50 µM β-mercaptoethanol and 1 
mg/ml BSA (Sigma-Aldrich) for 1h. For time-course experiments BaF3 or CFU-E cells were 
preincubated for 5 min at 37°C and subsequently stimulated with 0.5-50 U/ml Epo (Janssen-
Cilag) at 37°C. For each time point, 0.5x107 CFU-E cells or 1x107 BaF3-EpoR cells were 
taken from the pool of cells and lysed by adding 2x Nonidet P-40 lysis buffer, thereby 
terminating the reaction. 
4.3.2 Preparation of cellular lysates 
Detergent lysates of cells were prepared with 2x 1% NP40 buffer (1x buffer: 1% NP40, 150 
mM NaCl, 20 mM Tris pH 7.4, 10 mM NaF, 1 mM EDTA pH 8.0, 1 mM ZnCl2 pH 4.0, 1 mM 
MgCl2, 1 mM Na3VO4, 10% Glycerol) supplemented with 2 µg/ml aprotinin and 200 µg/ml 
AEBSF. After 30 min of incubation at 4°C, the lysate was centrifuged for 10 min at 20,000 g 
and 4°C. The supernatant was either used directly, processed further by immunoprecipitation 
or total cellular lysates were stored at -80°C. 
 
 
 
Materials and Methods  80 
4.3.3 Immunoprecipitation 
Immunoprecipitation was performed with an equivalent of 1x107 BaF3-EpoR or 0.5x107 CFU-
E cells by adding the target-specific antibody and 25 µl of Protein A or Protein G sepharose 
(GE Healthcare) to the lysate for 2-8 h or o/n at 4°C. The immunoprecipitates were washed 
twice with 1x 1% NP40 lysis buffer and once with TNE buffer (10 mM Tris pH 7.4, 100 mM 
NaCl, 1 mM EDTA, pH 8.0, 100 µM Na3VO4) and were resuspended in 25 µl 2x SDS sample 
buffer (1x buffer: 2% SDS, 50 mM Tris pH 7.4, 10% glycerol, 5% β-mercaptoethanol, 100 mM 
DTT, 0.01% bromphenolblue). Immunoprecipitates were immediately subjected to protein gel 
electrophoresis or stored at -20°C. Immunoprecipitates of pulse-chase experiments were 
washed four times with 1x RIPA buffer and twice with TNE buffer.  
Samples for time-course analysis of EpoR, JAK2, STAT5, CIS, SOCS3 or SHP-1 were 
prepared prior to immunoprecipitation by adding 40 ng of calibrator protein GST-EpoR 
(cytoplasmic domain), 18 ng of SBP-JAK2, 40 ng of GST-STAT5b, 2.3 ng SBP-CIS, and 1 ng 
SBP-SOCS3 to the lysates. Sample loading on SDS-PAGE was randomized to avoid 
correlated blotting errors (Schilling et al., 2005a). 
4.3.4 SDS-PAGE 
Proteins were separated according to their electrophoretic mobility in a denaturing SDS-
PAGE (Laemmli, 1970). Protein samples were boiled for 3 min in SDS sample buffer. Protein 
samples were separated by 10% SDS-PAGE with low bis-acrylamide (GE Healthcare) (Table 
2) and separated in a electric field in running buffer (192 mM glycine, 25 mM Tris, 0.1% 
SDS). Immunoprecipitates were centrifuged for 2 min at 15,700 g before loading. For total 
cellular lysates, an amount of 50-100 µg protein resuspended in 4x SDS sample buffer were 
separated by SDS-PAGE. 
 
 Stacking gel 
(10 ml) 
Separating gel 10% 
(20 ml) 
Separating gel 15% 
(20 ml) 
40% acrylamide 1 ml 5 ml 7.5 ml 
2% w/v methylenebisacrylamide 0.5 ml 1.3 ml 0.88 ml 
1M Tris-HCl, pH 6.8 1.25 ml - - 
1.5M Tris-HCl, pH 8.8 - 5 ml 5 ml 
10% SDS 0.1 ml 0.2 ml 0.2 ml 
ddH2O 7.15 ml 8.5 ml 6.42 ml 
APS (10 %) 100 µl 200 µl 200 µl 
Temed 10 µl 20 µl 20 µl 
 
Table 2. SDS-Page for 10% and 15% polyacrylamide gels. 
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4.3.5 Coomassie staining 
For Coomassie staining, gels were incubated in Staining Solution (0.25% Coomassie Brilliant 
Blue, 50% methanol, 12.5% acetic acid) for 10 min at room temperature. Subsequently, gels 
were incubated in Destaining Solution 1 (45% methanol, 10% acetic acid) for 10 min and in 
Destaining Solution 2 (5% methanol, 5% acetic acid) o/n at room temperature. 
4.3.6 Immunoblot analysis 
Immunoblotting was performed in semi-dry chambers (GE Healthcare) on nitrocellulose 
membranes with a pore size of 0.2 μm (Schleicher&Schuell).  
Blotting was performed in transfer buffer (192 mM glycine, 25 mM Tris, 0.075% SDS, 0.5 mM 
Na3VO4, 15% methanol) for 1 h at approximately 1.3 mA/cm2. Proteins were reversibly 
stained with Ponceau Red. After blocking unspecific antibody binding with 2-5% BSA diluted 
in TBS-T (10 mM Tris pH 7.4, 150 mM NaCl, 0.2% Tween-20), membranes were incubated 
with the appropriate first and secondary antibodies and proteins were visualized with the ECL 
or ECL Advance Western Blotting Detection Reagents (GE Healthcare) and subsequently 
detected on a Lumi-Imager F1TM (Roche Diagnostics, Mannheim). Quantification was 
performed using the LumiAnalyst 3.1 software (Roche Diagnostics, Mannheim). To evaluate 
total protein levels, membranes were incubated in stripping buffer (62.5 mM Tris pH 6.8, 2% 
SDS, 100 mM β-mercaptoethanol) for 20-25 min at 65°C, blocked with 2-5 % BSA diluted in 
TBS-T, and reprobed with the appropriate first and secondary antibody. 
4.3.7 Expression and purification of recombinant proteins in E.coli 
For high-efficiency expression of calibrator constructs, expression plasmids were 
transformed into competent E. coli BL21(DE3)CodonPlusRIL cells (Stratagene) as described 
for DH5α cells. A single positive colony was cultured in 25 ml LB medium supplemented with 
100 μg/ml ampicillin and 50 μg chloramphenicol at 37°C o/n. This o/n culture was then added 
to 225 ml fresh LB medium supplemented with ampicillin and chloramphenicol and cultured 
at 37°C for 90 min. After IPTG was added at a final concentration of 0.2 mM to induce protein 
expression, cells were cultured for another 3 h at 37°C. Cells were sedimented, washed with 
cold PBS and stored at -20°C o/n. 
Upon thawing the cell pellet was resuspended in 15 ml bacterial lysis buffer (10 mM Tris pH 
8.0, 100 mM NaCl, 1 mM EDTA) supplemented with 70 μl lysozyme solution (50 mg/ml) and 
75 μl 1 M DTT, and lysed on ice for 20 min. After adding 2.25 ml 10% N-lauroylsarcosine the 
suspension was vortexed for 1 min and sonicated (Sonopuls, Bandelin) three times for 1 min 
on ice. The bacterial lysate was then centrifuged at 15,000 g for 15 min at 4°C to remove cell 
debris. The supernatant was carefully transferred to a fresh tube and 350 μl Triton X-100 
were added. To bind GST- or SBP-tagged recombinant proteins, the supernatant was 
incubated with 500 μl glutathione sepharose beads or 500 μl streptavidin sepharose beads, 
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respectively, and rotated for 1 h at 4°C. Subsequently, beads were washed four times with 
cold 9% PBS, 1% NP40 supplemented with 5 mM DTT and once with cold PBS 
supplemented with 5 mM DTT. Beads were subsequently transferred to a 0,45 µm filter unit 
(Millipore) and recombinant proteins were eluted in fractions of 500 μl elution buffer (75 mM 
Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 5 mM DTT) supplemented with 20 mM reduced 
glutathione or 2 mM biotin for GST- or SBP-tagged proteins, respectively. Protein aliquots 
were stored at -80°C. 
4.3.8 Quantification of proteins 
To determine protein concentrations of cellular lysates the BCA Protein Assay Kit (Pierce) 
was used according to the manufacturer’s instructions. 
For quantification of recombinant calibrator proteins, a dilution series of the respective 
recombinant calibrator protein and a BSA standard series were separated by SDS-PAGE. 
The gel was Coomassie stained and band intensities were quantified using a Lumi-Imager 
F1 (Roche Diagnostics, Mannheim) and the LumiAnalyst 3.1 software (Roche Diagnostics, 
Mannheim). 
4.4 Antibodies 
The following antibodies were used for immunoprecipitation (IP) and immunoblot analysis 
(IB). 
primary antibodies use specification company 
mouse anti-phosphoTyr IB (1:10000) monoclonal, 4G10 UBI 
rabbit anti-EpoR 
IP (3 μl) 
IB (1:10000) 
polyclonal, M-20 Santa Cruz 
rabbit anti-JAK2 IB (1:10000) monoclonal, 24B11 Cell Signaling 
rabbit anti-JAK2  IP (1.5 μl) polyclonal, serum UBI 
rabbit anti-STAT5 
IP (5 μl) 
IB (1:10000) 
polyclonal, C-17 Santa Cruz 
rabbit anti-SOCS3 IB (1:1000) polyclonal, 16030 Abcam 
mouse anti-SOCS3 IP (8 µl) monoclonal, 1B2 Zymed 
rabbit anti-CIS IP (3 µl) polyclonal serum from rabbit 
goat anti-CIS IB (1:10000) polyclonal, N-19 Santa Cruz 
rabbit anti-SHP-1 
IP (3µl), IB 
(1:10000 
polyclonal, c-19 Santa Cruz 
rabbit anti-GFP IB (1 : 10000) polyclonal serum from rabbit 
 
Table 3. Primary antibodies. 
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conjugates use specification company 
donkey anti-rabbit IgG HRP IB (1:10000) polyclonal GE Healthcare  
sheep anti-mouse IgG HRP IB (1:10000) polyclonal GE Healthcare  
Protein A HRP IB (1:10000) - GE Healthcare 
donkey anti-goat IgG HRP IB (1:10000) ployclonal Santa Cruz 
 
Table 4. Secondary antibody conjugates used for immunoblot analysis. 
4.5 RNA analysis 
4.5.1 Extraction of total RNA 
Per time point total RNA from 3 x 106 primary erythroid progenitors was isolated using the 
RNeasy Mini Plus Kit (Qiagen). RNA was extracted according to the manufacturer’s 
instructions for suspension cells. To eliminate traces of DNA, on-column digests using the 
RNAse-free DNAse Set (Qiagen) were performed. RNA was stored at -80°C or directly used 
for quantification and reverse transcription. 
4.5.2 Quantification of RNA 
The concentration of total RNA samples was determined by measuring the absorbance of 
diluted 1:50 in TRIS buffer pH 7.4 at 260 nm (Ultrospec 3100 pro, GE Healthcare). 
4.5.3 Quantitative two-step RT-PCR 
To generate cDNA 1 µg of total RNA was transcribed with the QuantiTect Reverse 
Transcription Kit (Qiagen) according to the manufacturer’s instructions. Quantitative PCR 
(qPCR) was performed using a LightCycler 480 (Roche Diagnostics, Mannheim) in 
combination with the hydrolysis-based Universal ProbeLibrary (UPL) platform (Roche 
Diagnostics, Mannheim). In general, qPCR amplifications were performed in 96-well format 
in a 20 µl reaction volume containing 5 µl of 1:25 diluted template cDNA, 0.2 µM of forward 
and reverse primer, 0.2 µl of the appropriate UPL probe and 10 µl LightCycler 480 Probes 
Master solution (Roche Diagnostics, Mannheim) according to the manufacturer’s manual. 
Primer pairs were generated using the automated UPL Assay Design Center (www.roche-
applied-science.com). 
Crossing point (CP) values were calculated using the Second Derivative Maximum method of 
the LightCycler 480 Basic Software (Roche Diagnostics, Mannheim). PCR efficiency 
correction was performed for each PCR setup individually based on a dilution series of 
template cDNA. Relative concentrations were normalized using HPRT as a reference gene. 
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PCR step Temperature Time 
initial denaturation 95°C 5 min 
melting 95°C 10 s 
primer annealing 60°C 30 s 
50 cycles 
DNA synthesis and 
data acquisition 
72°C 1 s 
cooling 40°C 2 min 
 
Table 5. PCR program for quantitative PCR. 
 
4.5.4 Microarray analysis 
The quality of total RNA samples, extracted from 3×106 CFU-E or 3×106 BaF3-EpoR cells 
was assessed with the Bioanalyzer 2100 (Agilent) to ensure that 28S/18S rRNA ratios were 
in the range of 1.5 to 2.0 and concentrations were comparable between samples. In total, 12 
microarrays were used in the analysis comprising stimulations with 0.5 U/ml Epo for 0, 1, 2, 
3, 4, 5, 6, 7, 8, 14, 19, 24 h and unstimulated control. 
Raw microarray data were processed using the R environment (www.r-project.org) together 
with the Bioconductor toolbox (www.bioconductor.org). Normalization was performed using 
the variance stabilization algorithm (vsn) available in Bioconductor (Huber et al., 2002). 
Quality of the results has been assessed using made4, an R package for multivariate 
analysis of gene expression data (Culhane et al., 2005). Subsequent probe annotation was 
handled with the Bioconductor package annaffy. The logarithmic gene fold expression was 
calculated with respect to the gene expression at 0 hours. The gene expression kinetic from 
each experiment was ranked according to the absolute value of the combined mean and 
peak fold expression. 
4.6 Mathematical modeling 
4.6.1 Computational data processing 
Randomized quantitative immunoblotting data was processed using GelInspector software 
(Schilling et al., 2005a). The addition of normalizers allowed for quality control and 
normalization of the raw data. The following normalizers were applied: GST-EpoR for EpoR 
and pEpoR, SBP-JAK2 for JAK2 and pJAK2, SPB-CIS for CIS and SBP-SOCS3 for SOCS3. 
For first estimates, cubic smoothing splines were used (MATLAB csaps function with 
smoothness parameter 0.3). For background correction, the lowest value of a time-course 
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was generally subtracted from all data points for all observed species. For estimation of the 
percentage of phosphorylated STAT5, the ratio of the shifted and the total fraction in the 
STAT5 immunoblot was determined.  
4.6.2 Scaling factors and error estimation 
Immunoblotting measurements typically yield relative concentrations, while the model is 
formulated in absolute concentrations. Therefore, immunoblotting data was scaled to 
numbers of molecules per cell. As the quality of a mathematical model is determined by its 
deviation from the data relative to the measurement error, the variability of the data had to be 
estimated. All stimulation experiments were performed at least twice with reproducible 
results. To estimate the error of the immunoblot results by a linear error model, the standard 
deviations of the replicates were plotted against the mean value of the respective data 
points. A linear regression was fitted yielding approximately a 15 % relative error and a 5 % 
absolute error. This error estimation confirms the approximately 20 % error of the 
immunoblotting technique determined in previous studies (Schilling et al., 2005a). 
4.6.3 Parameter estimation 
Parameter estimation was performed using the software PottersWheel (Maiwald et al., 2008). 
Each fit was performed with a deterministic trust region optimizer with χ2 tolerance of 10-6 and 
fit parameters tolerance of 10-6. All parameters were estimated with boundaries between 10-6 
and 103, and none of the estimated parameters lay on these boundaries. Additionally, 5000 
fits using random numbers as initial guesses for parameters, were computed to analyze the 
distribution of the parameter estimations. For this analysis only fits with comparable low χ2 
values (4% of 5000 fits) were used. This analysis confirmed a global parameter optimum for 
all parameters, showing identifiability of our model. 
Confidence intervals on the parameters were calculated using a likelihood-based approach 
that systematically scans the profile likelihood in the parameter space to infer point-wise 
confidence intervals. 
4.6.4 Sensitivity analysis 
Sensitivity analysis was applied to investigate relative changes of derived system variables K 
as a result of relative changes in parameter values pi 
i
iK
p p
K
K
p
S
i ∂
∂
⋅=              (1) 
The control coefficients quantify the extent to which a characteristic of the dynamic time 
profile (such as the signalling amplitude, the duration, or the integrated output) is controlled 
by the processes in the mathematical model (Hornberg et al., 2005a). The software 
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PottersWheel (Maiwald et al., 2008) was used to calculate the control coefficients of the 
calibrated model. 
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6 Appendix 
6.1 Ordinary differential equations model to study JAK2/STAT5 amplification 
Ordinary differential equations (in power law terms) 
 
 
 
 
 
 
(1) 
 
(2) 
 
(3) 
 
(4) 
 
(5)
 
Logarithmic amplification factor 
To analyze how the Epo-induced signal is amplified through the JAK2/STAT5 pathway, the 
logarithmic amplification factor (LA) between the two activated intermediates X* and Y* was 
defined. 
 
 
(6)
 
T is the duration of stimulation and LA is the logarithm of the ratio between the production of 
the two intermediates. The total production of an intermediate is described by the integral of 
the net activation rate during the stimulation process. Considering this definition, a system 
amplifies between two steps in the pathway when LA is higher than zero (Vera, Bachmann et 
al, 2008). 
 
 
Fig. S1. Logarithmic amplification (LA) for different 
values of sustained Epo simuli. The LA was 
determined to analyze the amplification between the 
phosphorylated EpoR/JAK2 complex and 
phosphorylated STAT5 in the nucleus. The 
physiological serum concentration of Epo, (7.9×10-3 
U/ml: long-dashed line) and the concentration of Epo 
used in the experiments (5 U/ml: short-dashed line) are 
indicated. Eposs: Epo (Vera et al., 2008). 
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6.2 Validation of time-resolved mRNA induction of SOCS3 and CIS by RT-PCR 
Results from expression profiling by microarray analysis were validated for CIS and SOCS3 
mRNA levels in CFU-E cells using quantitative RT-PCR. After stimulation of CFU-E cells with 
5 U/ml Epo fold changes in CIS and SOCS3 mRNA levels were analysed for different 
timepoints. Relative concentrations were normalized using the second generation 
housekeeper HPRT as a reference (Vandesompele et al., 2002). The fold induction was 
calculated with respect to the expression at 0 h. 
  
 
Fig. S2. Induction of Epo-induced mRNA levels of CIS and SOCS3 in CFU-E cells using 
quantitative RT-PCR. Fold changes in CIS and SOCS3 mRNA levels after stimulation of CFU-E cells 
with 5 U/ml Epo were analysed for different timepoints. Relative concentrations were normalized with 
HPRT and the fold induction was calculated with respect to the expression at 0 h. 
 
6.3 Ordinary differential equation model of the JAK2/STAT5 pathway in CFU-E cells 
Ordinary differential equations (ODE) are shown for the dynamic JAK2/STAT5 pathway 
model in primary CFU-E cells. Parameter values of the best fit including 1σ confidence 
intervals are displayed. 
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6.4 Identifiability analysis 
     
Fig. S3. Identifiablity analysis by fit sequence analysis. (a) Box plots of all estimated parameters 
are shown for the best 4% of 5000 fits. Three parameters have a standard deviation larger than 25%. 
(b) Non-parametric bootstrap-based algorithm for identifiability testing (NBI) revealed parameter 
dependencies for a set of two and three parameters, respectively. SHP-1 activation by EpoR_vmax 
(shp_act_r_vmax) show a linear relationship to EpoR deactivation by SHP-1 (r_dea_shp) as well as 
to JAK2 deactivation by SHP-1 (jak_dea_shp). (c) The parameter SHP1 activation by EpoR_vmax 
was fixed and parameter estimation was repeated. Box plots of all estimated parameters are shown 
for the best 4% of 5000 fits. All parameters show a standard deviation smaller than 35% (data 
provided by M.Schilling, DKFZ, Heidelberg). 
 
b 
c 
a 
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6.5 Abbreviations 
7-AAD 7-aminoactinomycin D 
BFU-E burst forming unit-erythroid 
bp base pairs 
BSA bovine serum albumin 
CD cluster of differentiation 
cDNA complementary DNA 
CFU-E colony forming unit-erythroid 
CFU-GEMM colony forming unit-granulocytes, erythrocytes, monocytes, macrophages 
CIS cytokine-inducible SH2 domain-containing protein 
d days postconception 
DMEM Dulbecco’s modified eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphate 
Dox doxycycline 
DTT dithiothreitol 
E. coli Escherichia coli 
ECL enhanced chemiluminescence 
EDTA ethylenediaminetetraacetic acid 
EGFR epidermal growth factor receptor 
EGFP enhanced green fluorescent protein 
Epo erythropoietin 
EpoR erythropoietin receptor 
ER endoplasmic reticulum 
FACS fluorescence activated cell sorter 
FCS fetal calf serum 
FLC fetal liver cells 
g g force 
G418 geneticin 
Gab Grb2-associated binder 
G-CSF granulocyte colony-stimulating factor 
GFP green fluorescent protein 
GHR growth hormone receptor 
Grb growth factor receptor-bound protein  
h hours 
HA hemagglutinin 
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HBS hepes buffered saline 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HIF hypoxia-inducible transcription factor 
HRP horseradish peroxidase 
HSC hematopoietic stem cell 
IB immunoblot 
Ig immunglobulin 
IL interleukin 
IMDM Isocove’s modified Dulbecco’s medium 
IP immunoprecipitation 
JAK Janus kinase 
kDa kilodalton 
LB Luria Bertani broth 
M molarity 
MAPK mitogen-activated protein kinase 
min minutes 
ml milliliter 
µl microliter 
neo neomycin resistance gene 
nm nanometer 
o/n over night 
ODE ordinary differential equations 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDGFR platelet-derived growth factor receptor 
PE phycoerythrin 
Pfu Pyrococcus furiosus 
PI3K phosphatidylinositol 3-kinase 
PKB protein kinase B 
PKC protein kinase C 
puro puromycin 
rhEpo recombinant human erythropoietin 
rpm rounds per minute 
RT room temperature 
SBP streptavidin-binding peptide 
SCF stem cell factor 
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SDS sodium dodecyl sulfate 
SH Src homology 
SHP SH2 domain-containing protein tyrosine phosphatase 
SOCS suppressor of cytokine signaling 
Sos son of sevenless 
STAT signal transducer and activator of transcription 
strep streptavidin 
TAE  Tris-acetate-EDTA 
Taq Thermus aquaticus 
TB Terrific broth 
TBS Tris buffered saline 
TBST Tris buffered saline with Tween-20 
TE Tris-EDTA 
Tet tetracycline 
TfR transferrin receptor 
TM transmembrane 
TPO thrombopoietin 
Tris Tris(hydroxymethyl)-aminomethane 
U unit of enzyme activity 
WEHI Walter and Eliza Hall Institute 
w/v weight per volume 
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